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 Marine natural products are emerging source as an attractive drug pipeline based on 
its enormous biological diversity of origin. Technical advances like scuba diving, 
manned submarine boosted the interest to the marine natural products three decades 
ago and there are eight approved marine drugs now. Most of the approved drugs are 
based on marine natural products isolated from marine invertebrates, but recent study 
suggest that most of them are produced by microorganisms. In this study, 
actinomycetes were isolated from marine envirionments and investigated to discover 
a novel and bioactive marine natural products.  
 A chemical investigation of the actinomycetes, Nocardiopsis sp. CNQ115 isolated 
from marine sediment collected off the coast of southern California resulted in the 
isolation of two novel imidazole natural compounds nocarimidazoles A and B. The 
chemical structures of nocarimidazoles A and B were determined by interpretation 
of NMR data analyses. No significant antibacterial or cytotoxic activities were 
observed. Investigation of the chemical components of a Streptomyces sp. 10A085 
isolated from mudflat sediments collected on the southern coast of the Korean 
peninsula led to isolation of four new compounds, anithiactins A – D. The chemical 
structures of anithiactins were determined by interpretation of NMR data analyses, 
while the chemical structure of anithiactin B was established from a combination of 
NMR spectroscopic and crystallographic data analysis. Anithiactins A – C displayed 
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Chapter 1. Marine Natural Products as a New 
Pharmaceutical Pipeline 
  1.1 History of Natural Products as a Source for Drug 
Development 
 From old days, natural products have been used as a drug source. Before the modern 
age, natural products were used as a form of extract or plant materials. The oldest 
written record of medicinal plant was shown on the clay slab at Sumeria 
approximately 5,000 years ago which described 12 recipes for drug preparation from 
more than 250 different plants (Kelly, 2009). In China, medical usage of Rhei 
rhisoma (rhubarb), camphor, Theae folium (tea tree), ginseng, cinnamon bark, 
ephedra and many other medicinal plants were known since 2,500 BC, and these 
plant are still widely used over eastern and southern Asia (Bottcher, 1965; Wiart, 
2006). After that, all through the history of mankind, continuous efforts to look for 
the healings were enormous and results were pass throughout the millennia 
(Petrovska, 2012).  
 After the advance of the science and technology in modern centuries, some of these 
medicinal plant become medicine after extraction, isolation and quantification. This 
technical improvement resulted in the development of many drugs such as khellin, 
metformin and verapamil. The khellin was isolated from plant Ammi visnaga Lamk 
and used as a bronchodilator. Efforts to reduce the side effects of khellin led to the 
development of chromolyn (used in the form of sodium chromoglycate). The 
galegine was isolated from the plant Galega officinalis L. as a major active 
ingredient of anti-hyperglycemia. The metformin was developed from galegine with 
2 
its main chemical structure maintained. The papaverine isolated from Papaver 
somniferum was advanced to verapamil to treat hypertension (Farbricant & 
Farnsworth, 2001). This medicinal plant is also well-known as a source of morphine 
and codeine (Buss & Waigh, 1995).  
 
 
Figure 1.1 Drugs developed from medicinal plants 
 
 However, the most famous example of medicinal plant derived medicine would be 
the antimalarial drugs development. First generation antimalarial drugs, such as 
chloroquine and mefloquine, were developed from quinine which was isolated from 
the bark of Cinchona sp. This plant extracts was used to treat fevers around the 
Amazon region traditionally. Spread of quinine-class resistance malaria led to the 
2 
discovery of artemisinin isolated from the plant Artemisia annua and the 
development of artemisinin class antimalarial drugs. This plant has been used to treat 
fevers in China for a long time (Wongsrichanalai et al., 2002). Artemisinin class 
drugs are deployed to combat malaria all across the world, even though its 
mechanism of action not clear (O'Neill & Posner, 2004; O'Neill et al., 2010; Wang 
et al. 2010). 
 
 
Figure 1.2 Antimararial drugs developed from medicinal plants 
  
 Likewise, using natural products as drug lead was deployed as useful tactics to 
combat other disease includes anticancer (Gueritte et al., 2005; Roussi et al., 2012) 
and antihypertensive (Cordell & Colyard, 2012). The analysis of the sources of small 
4 
molecule shows this trend clearly. Figure 1.3 is showing classified new drugs from 
1981 to 2010 based on its origin as synthetic (S) or natural product (N). It revealed 
that two thirds of the small molecules are natural products or natural products 
inspired. Only one third can be categorized as truly synthetic (Newman & Cragg, 
2012). Conclusively, natural products are major pipelines for developing drugs now 
and then (Cragg & Newman, 2013). 
 
 
Figure 1.3 Sources of drugs [N (an unmodified natural product), NB (a natural 
product botanical), ND (a modified natural product), S (a synthetic compound with 
no natural product conception), S*, S*/NM (a synthetic compound with a natural 
product pharmacophore; /NM indicating competitive inhibition), S/NM (a synthetic 
compound showing competitive inhibition of the natural product substrate)] (Cragg 
& Newman, 2013) 
 
  1.2 Marine Natural Products as a New Pharmaceutical Pipeline 
    1.2.1 Novelty of Marine Natural Products 
 Unlike its counter parts, marine resources were not used much as a medicinal 
sources for long time. Before scuba diving technique spread widely, collection of 
marine organisms under the water surface was very limited to specifically trained 
5 
professionals. Recent introduction of various technical advances like scuba, 
dredging, manned submarine and remotely operated vehicles gives more chance to 
address the marine resources. And this makes marine resources as a more attractive 
drug discovery pipeline. Currently, more than 30,000 marine natural products were 
reported and number is increasing (Blunt & Munro, 2008). 
 The most interesting character of the marine natural product is from biodiversity of 
marine organisms. For examples, there is only 1 terrestrial exclusive phylum among 
the 33 animal phyla. On the other hand, there are 15 of marine exclusive phyla and 
5 of the rest phyla have more than 95% of their species in marine (Margulis & 
Schwarts, 1988). This enormous number of marine animal species and phyla may 
due to the oldness and wideness of the ocean environment then terrestrial one. As 
terrestrial organisms are descendants of marine life and 70% of the earth surface is 





Figure 1.4 Number of estimated species of animal phyla in terrestrial and marine 
environment (Margulis & Schwarts, 1988, modified) 
 
 It is clear that more number of the species gives more chance to discover novel 
chemical structures. One of the Chinese chemistry group quantified the novelty of 
marine natural products (Kong et al., 2010). They categorized the known natural 
products from Dictionary of Natural Products and Dictionary of Marine Natural 
Products to the each of the specific ‘scaffolds’ which are defined as the contiguous 
ring systems with chains that link them. This scaffold analysis gave that there are 
163,089 terrestrial natural products using 25,289 scaffolds and 31,772 marine natural 
products using 5276 scaffolds. And more than 70% of marine scaffolds are using 


























































































































































































































































































Figure 1.5 Number of scaffolds accord with number of marine natural products 
(Kong et al., 2010) 
 
    1.2.2 Marine Drugs on the Market 
 There are eight Food and Drug Administration (FDA) and European Medicines 
Agency (EMEA) approved drugs (Meyer, 2014). The four of marketed drugs are 
used to treat cancer (Adcetris, Cytoser-U, Halaven, Yondelis), two for virus 
(Carragelose, Vira-A) and each of one for hypertriglyceridemia and neuropathic pain 
(Lovaza and Prialt). Three of these are employed to drug as natural product itself 
(Prialt, Yondelis, Carragelos) and others took modifications to solve the supply and 
ADMET properties problems. Regarding origin of the drugs, six of marine drugs 
were obtained from marine invertebrates like tunicate, sea hare, marine snail and 




Figure 1.6 Chemical structures of marine drugs on the market divided by 
therapeutic area (Martins et al., 2014 modified) 
 
 Marine drug pipelines is listed with nine more drug candidates under clinical trials 




Table 1.1 The marine drugs on market (Martins et al., 2014) 
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 Marine invertebrates are major supply for the marine drugs. It is because the many 
of marine natural products were obtained from marine invertebrates (Hu et al., 2011). 
(Figure 1.7) Within the marine invertebrate, sponge and coral were the main sources 
for the marine natural products. These animals are taking unique ecological roles to 
support the diversity of marine ecosystem. Coral reef are supporting up to 40% of 
all fish species while taking only 0.1% of ocean area around the tropical zone (Moyle 
& Cech, 2003). Sponges inhibit all around the ocean from polar area to the deep 
ocean trench bottom and associated with a wide variety of microorganisms (Taylor 
et al., 2007). It is known that from half to 80% of sponge weight is considered be 
that of associated bacteria. Both of these animals are filter-feeder, and providing 
physical shelters to around environment. However, the fact that marine invertebrates 
are main source of the marine drug is one of the main obstacle to overcome for the 
development of marine drugs that industrial scale cultivation technique for the most 







Figure 1.7 Temporal trends in the number of novel compounds isolated from 
different marine organisms between 1985 and 2008. [▲, marine invertebrate; ■, 
marine algae; ◆, Marine microorganisms (including phytoplankton).] (Hu et al. 
2011) 
 
    1.2.3 Major Hurdle of Marine Natural Products derived Drug Discovery 
 As described ahead, marine natural products have potentials as attractive drug 
pipeline and are taking more and more interests. However, there are several problems 
to overcome.  First of all, availability problems are still not neglectable. Despite of 
the introduction of many advanced methods, marine resource is not much close 
enough. Average depth of the open ocean is more than four thousand m, but general 
scuba technique allow us to only 40 m deep. Even with the most latest diving 
technique with atmospheric diving suit, depth reach is less than 700 m. The dredging 
is not considered these days for it is not eco-friendly and it is too much random 
sampling method. The budget for manned submarine is not available for most of the 
research group and even for the big pharmaceutical company. Recent introduce of 
12 
remotely operated vehicles can be a good alternative for most of the collection 
methods.  
 Second problem is biodiversity itself. As describe above, estimated number of 
marine organism is enormous. But there is not enough research infra to support that 
research. For example, sponge is one of the major source for the marine natural 
products for several decades, but convenient molecular level identification method 
like 16S RNA sequencing of microorganisms for this phylum is still under 
construction (Vargas et al., 2012). To have the desired result from this enormous 
resource, we need to set specific strategy considering ecological back ground and 
marine taxonomy.  
 Third and most important problem is supply. This issue can link with first addressed 
availability problem. As described above, most of the marine drugs were developed 
from invertebrate derived marine natural products. And most of those marine drug 
on market was 20 to 40 year after the first report of the natural products. It is mainly 
because of the supply problem that most of the industrial scale culture technique for 
marine invertebrate are not available yet. Those years are more than couple of 
decades longer than common process from terrestrial natural products. Most of these 
time gap used on the establishment of synthetic method for marine natural products 
supply. For example, Taxol was notorious for its supply problem. At early stage of 
discovery, 10 g of Taxol was isolated from 1,200 kg of Taxus brevifolia bark 
(Goodman & Walsh, 2001). Yield was low, but it was possible to do it. But it is not 
possible for marine natural products. There is no detailed research database of 
distribution of marine organisms as the forestry, also there is no industrial 
background to collect the marine organisms like the timber industry. 
13 
 Yondelis is good example of marine drugs which solve the supply problem with 
creative way. It was first isolated from tunicate Ecteinascidai turbinate (sea squirt) 
and elucidated in 1984 (Rinehart, 2000). At the early stage of discovery, it was 
supplied from sea squirt at extremely low yield. Based on its anticancer activity and 
novel chemical structure, many synthetic preparation methods were developed to 
meet the requirement of this drug for clinical trials. But break-through was on other 
way. The Spanish pharmaceutical venture company PharmaMar devised 
semisynthetic process from Safracin B, which was obtained from bacterium 
Pseudomonas fluorescens by fermentation. This intuition from Yondelis with other 
recent discovery suggest that actual producer of most current marine drug from 
marine invertebrates are symbiotic microorganisms (Gerwick & Moore, 2012). This 
also emphasize the importance of marine microorganisms as attractive drug 
discovery pipeline.  
 
 
Figure 1.8 Supply of yondelis (Cuevas & Francesch, 2009) 
 
 In this study, sponge and marine microorganisms were screened to discover novel 
natural products. Sponge was screening target as the traditional marine natural 
products source. Marine microorganisms from bottom sediment were isolated and 
13 
screened. Mudflat was selected for new source of marine microorganisms, based on 
its environmental uniqueness, and isolated microorganisms were screened. Obtained 




Chapter 2. Marine Natural Products from Sediment-
Derived Actinomycetes 
  2.1 Introduction 
 Actinomycetes are the most economically and biotechnologically valuable 
prokaryotes due to the discovery of wide range of bioactive secondary metabolites, 
such as antibiotics, antitumor agents, and immunosuppressive agents (Ravikumar et 
al, 2011). More than 15,000 bioactive molecules were produced by these microbes 
including many that are used as drugs today. As the soil-derived microorganisms 
have been intensively investigated for discovering therapeutically important 
molecules over a half century (Fenical, 1993), the frequency of new compounds 
discovery has been decreased. Therefore, an unexplored environment needs to be 
searched for isolating different microorganisms found in terrestrial environments. 
Recently, microorganisms isolated from the marine environments including the deep 
sea sediments and marine organisms, have been considered as a good source for 
exploring new natural products (Takami et al., 1997). In particular, marine 
actinomycetes have different characteristics from those of terrestrial counterparts 
that produced unprecedentedly secondary metabolites with diverse biological 




  2.2 Results and Discussion 
    2.2.1 Structure Elucidation of Nocarimidazoles from CNQ115 
 As part of our ongoing research to discover new bioactive compounds from marine-
derived actinomycetes, strain CNQ115, identified as Nocardiopsis sp. from marine 
sediments collected off the coast of southern California was investigated. The genus 
Nocardiopsis has been shown to be phylogenetically coherent and to represent a 
distinct lineage within the order Actinomycetales (Rainey et al., 1996). Nocardiopsis 
strains are ubiquitous in the environment and are frequently isolated from habitats 
with moderate to high salt concentrations such as saline soils, marine sediments, and 
salterns (Sabry et al., 2004). The strains of Nocardiopsis have also been reported to 
produce a variety of biologically active agents including the cytotoxic antifungal 
antibiotic kalafungin (Bergy, 1968), the antibiotic 3-trehalosamine (Dolak et al., 
1980), the protein kinase C inhibitor methylpendolmycin, and a staurosporine-like 
inhibitor of a cyclic AMP-dependent protein kinase (Peltola et al., 2001). LC-MS 
guided fractionations has led to two new natural products, nocarimidazols A (1) and 
B (2). Herein, we report the isolation and structure characterization of 
nocarimidazols A and B. 
 Imidazole derivatives were intensively studied for its pharmacological properties on 
various range of biological activities like analgesic and anti-inflammatory (Suzuki 
et al., 1992), anti-fungal (Johnson et al., 1999; Brewer et al., 1987) and anti-viral 
(Sharma et al., 2009). And many of prescription drugs have imidazole as a key 
pharmacophore (Zhang et al., 2014). Dacarbazine, well-known skin cancer and 
Hodgkin disease drug (Eggermont & Kirkwood, 2004), shares key chemical 
structure with nocarimidazoles, having carboxylic carbon and additional nitrogen at 
17 
4 and 5 position of imidazole ring. Also, many natural products with imidazole 
moiety have been reported (Jin, 2011). But, natural products which have 4-
carboxylic carbon with imidazole ring is very rare. And imidazole natural products 
with 4-carboxylic carbon and 5-amine group is not reported yet. 
 
 
Figure 2.1 Imidazole-based anticancer drugs (Eggermont & Kirkwood, 2004) 
 
     2.2.1.1 Nocarimidazole A (1) 
Actinomycete strain CNQ115, obtained from marine sediment sample collected off 
the coast of southern California, at a depth of 51 m, required seawater for growth. 
This strain shares 99.3% 16S rRNA gene sequence identity with its nearest neighbor, 
Nocardiopsis sp. The strain was cultured at 25 °C by rotary shaking in 8 replicate 
2.5-L Ultra Yield Flasks each containing 1 L of the medium for seven days. The 
broth was extracted with EtOAc and evaporated under reduced pressure to yield an 
18 
extract, which was subjected to flash chromatography followed by HPLC to afford 
pure samples of nocarimidazols A (1) and B (2). 
Nocarimidazols A (1) was obtained as a red amorphous solid. Its molecular formula 
was established as C13H23N3O based on HRESIMS (obsd [M + H]+ at m/z 238.1918), 
implying 4 degrees of unsaturation. The UV spectrum of 1 displayed absorption 
bands at 300 nm, indicating the presence of a significant chromophore in the 
molecule. The IR spectrum of 1 showed the presence of a primary amine (3433 and 
1640 cm-1) and an α, β-unsaturated carbonyl group at 1678 cm-1. Two substructures, 
a linear aliphatic chain and a imidazole moiety, were assigned by analyses of 1H, 13C, 
COSY, HSQC, and HMBC NMR spectroscopic data recorded in CDCl3 (Tables 2.1). 
The 1H NMR spectrum of 1 displayed a downfield singlet proton [(δH 7.80, s)]. The 
presence of alkyl chain moiety was suggested by a methyl doublet integrating for six 
hydrogens [δH 0.82, (d, J = 6.6 Hz)] and overlapping methylene proton signals [δH 
1.03 - 1.32, (m)] and one methine proton [δH 1.46, (m)] and two downfield methylene 
proton [δH 1.62 (q, J =7.4 Hz), 2.68 (t, J = 7.4 Hz)]. The COSY cross peaks of H3-
14 and H3-15 to H-13 indicated that these methyls were coupled to a methine proton 
(Table 2.1). The terminal gem dimethyl protons (H3-14 and H3-15) at δH 0.82, which 
showed HMBC correlations to C-13 (δC 27.9), and to C-12 (δC 38.9). The proton 
signal (δH 1.11) derived from H2-12 showed a HMBC correlation to C-11 (δC 27.2). 
These NMR data established a 2-methylbutane unit.  
The proton signal (δH 2.68) derived from H2-7 showed a COSY correlation to an 
aliphatic methylene proton signal at δH 1.62 (H2-8), which in turn showed a COSY 
correlation to another aliphatic methylene proton signal at δH 1.29 (H2-9). The proton 
signal (δH 2.68) derived from H2-7 also showed HMBC correlations to a carbonyl 
C-6 (δC 190.9). These NMR data established a pentanone unit. 
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The alkyl chain moiety was final established by HMBC correlation from the 
methylene protons H2-11 to the carbons C-9. The HMBC correlations from the 
singlet proton H-2 (δH 7.80, s) to carbons C-4 (δC 146.9) and C-5 (δC 111.7) and the 
molecular formula of 1 allowed the construction of a imidazole ring moiety. Lastly, 
the connection between the alkyl chain moiety and the imidazole ring moiety was 
achieved by the long range HMBC correlations from an olefinic proton H-2 to 
carbonyl carbon C-6 allowed the assignment of nocarimidazols A to be completed, 
as shown in Figure 2.2. 
 
 








Table 2.1 Physical and spectral properties of nocarimidazole A (1) 
Red amorphous solid 
Molecular formula: C13H23N3O, 
HRFABMS: m/z 238.1918 [M+H]+ (calcd for 238.1919) 
IR (KBr) vmax: 3433, 3054, 2928, 2360, 1678, 1640, 1384, 1265, 1201, 1140, 839, 749 cm-1 
1H and 13C NMR dataa (CDCl3) 
 
No. 
              1 
C, mult.b H (J in Hz) 
2 130.2, CH 7.80, s 









2.68, t (J = 7.4) 
8 24.1, CH2 1.62, q (J = 7.4) 
9 29.7, CH2 1.29, m 
10 38.8, CH2 1.22, m 
11 27.2, CH2 1.24, m 
12 38.9, CH2 1.11, m 
13 27.9, CH 1.47 dp (J = 13.1, 6.6) 
14 22.5, CH3 0.82, d (J = 6.6) 
15 22.5, CH3 0.82, d (J = 6.6) 
a 500 MHz for 1H NMR and 125 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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      2.2.1.2 Nocarimidazole B (2) 
Nocarimidazols B (2) was obtained as a red amorphous solid. Its molecular formula 
was established as C14H25N3O based on HRESIMS (obsd [M + H]+ at m/z 252.2075), 
implying 4 degrees of unsaturation. The UV absorption spectrum of 2 showed an 
absorption band at 300 nm, which was identical with the UV data obtained from 
nocarimidazols A (1). The IR spectrum of 2 was also identical to that of 1. The 1H 
NMR spectrum of 2 was almost identical to that of 1 except for the presence of one 
additional methylene resonance and the presence of one methyl triplet (δH 0.84) and 
methyl doublet (δH 0.78). The 13C NMR data of 2 were also similar to those of 1 
except for additional carbon signals at C-14 [δC 36.5] (Table 2.2). The interpretation 
of 2D NMR spectroscopic data permitted the identification of the structure of 2. 
 
 
Figure 2.4 Chemical structure of nocarimidazole B (2) 
 
To confirm the imidazole moiety of compound 2, methyl derivative (3) was 
prepared with diazomethane. A down field singlet (δH 3.42) was observed at 
1H NMR spectrum of compound 3 and the HMBC correlations from the 
singlet proton 3-NCH3 (δH 3.42) to C-2 (δC 130.9) and C-4 (δC 144.6) was 
clear to assign the position of N-3 within imidazole ring. However, to clarify 
the position of rest of nitrogen, dimethyl derivative of compound 2 was 
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prepared with iodomethane. This dimethyl derivative (4) of compound 2 
showed two down field singlets and the HMBC correlations from the singlet 
proton 1-NCH3 (δH 3.95) to C-2 (δC 130.6) and C-5 (δC 107.8) established the 
position of N-1 in imidazole ring. Those HMBC correlations observed from 
methyl derivatives of nocarimidazole B clarify the position of nitrogens and 
quaternary carbons within the imidazole ring as shown in Figure 2.5. 
 
 
Scheme 2.1 Methylation reaction of nocarimidazole B (2) 
 
 
Figure 2.5 Key HMBC correlations of nocarimidazole B (2) 
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Table 2.2 Physical and spectral properties of nocarimidazole B (2) 
Red amorphous solid 
Molecular formula: C14H26N3O, 
HRFABMS: m/z 252.2075 [M+H]+ (calcd for 252.2076) 
IR (KBr) vmax: 3433, 3054, 2926, 2855, 1678, 1548, 1455, 1384, 1203, 1140, 839, 722 cm-1 
[α]D + 1.42° (C 0.42, MeOH) 




C, mult.b H (J in Hz) 
2 130.5, CH  7.75, s 









2.68, t (J = 7.4) 
8 24.1, CH2 1.62, q (J =7.4)  
9 26.9, CH2 1.26,m 
10 29.4, CH2 1.07, m 
11 29.5, CH2 1.26, m 
12 29.3, CH2 1.26,m 
13 34.3, CH 1.25, m 
14 36.5, CH2 1.05, m 1.23, m 
15 11.3, CH3 0.84, t (J = 9.0) 
16 19.1, CH3 0.78, d (J = 9.0) 
a 500 MHz for 1H NMR and 125 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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  2.2.2 Bioactivities of Nocarimidazoles A and B 
The cytotoxicities were evaluated with MTT assay on A498 and ACHN renal cancer 
cell lines, but no significant cytotoxicities were observed. There were no 
antibacterial activities either, on MIC assay. Interestingly, AChE inhibitory activity 






    2.3.1 Instruments and Data Collection 
The optical rotation was measured using a Autopol III (Rudolph Research, USA) 
polarimeter with a 5 cm cell. IR spectra were obtained with a Varian Scimitar Series. 
CD spectra were collected in a ChirascanTM-plus (Applied Photophysics, UK) 
spectrometer with a 0.5 mm pathlength rectangular cuvette. NMR spectra were 
recorded on Varian Inova NMR spectrometer (500 and 125 MHz for 1H and 13C 
NMR, respectively), using the signals of the residual solvent protons and the solvent 
carbons as internal references (δH 7.24 and δC 77.0 ppm for CDCl3). EI-MS spectra 
were measured on a JEOL, JMS-AX505WA mass spectrometer. Low resolution LC-
MS data were measured using an Agilent Technologies 6120 quadrupole LC/MS 
system with a reversed phase column (Phenomenex luna C18(2) 100 Å , 50 mm × 
4.6 mm, 5 μm) at a flow rate of 1.0 mL/min. Column chromatography was performed 
using Silica gel 60 (0.040 ~ 0.063 mm, Merch), normal-phase methods. The fractions 
were separated by WATERSTM 616 quaternary HPLC pump, WATERSTM 996 
photodiode array detector using an Phenomenex luna C18(2) (250 mm × 10 mm, 5 
μm) reversed-phase HPLC column. 
 
    2.3.2 Microorganism Isolation and Fermentation 
Nocardiopsis sp. (CNQ115) was isolated from marine sediments collected off the 
coast of southern California. It was classified according to 16S rRNA analysis with 
99.3% identity. Strain CNQ115 was cultured in 8 2.5-L Ultra Yield Flasks each 
containing 1 L of the medium (10 g/L of soluble starch, 2 g/L of yeast, 4 g/L of 
peptone, 10 g/L of CaCO3, 20 g/L of KBr, 8 g/L of Fe2(SO4)3·4H2O dissolved in 750 
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mL natural seawater and 250 mL of distilled water) at 25 °C with shaking at 150 
rpm. After 7 days, the broth was extracted with EtOAc and evaporated under reduced 
pressure to yield an extract of CNQ115 (1.2 g). 
 
    2.3.3 Extraction and Compound Isolation 
The crude extract (1.2 g) was subjected on open column chromatography on silica 
gel (30 g), eluted with a step gradient of dichloromethane and methanol. The 
dichloromethane/methanol (10:1) fraction contained a mixture of metabolites, which 
was purified by reversed-phase HPLC (Phenomenex Luna C-18 (2), 250×100 mm, 
2.5 mL/min, 5 μm, 100 Å , UV = 254 nm) using an isocratic solvent system of 45% 
CH3CN in H2O to afford nocarimidazols A (1, 18.0 mg) and B (2, 25.0 mg). 
 
    2.3.4 Methylation Reactions 
Nocarimidazole B Diazomethane Derivative (3); Freshly prepared diazomethane 
reagent (0.5 mL) was added to a 1 mL MeOH solution of 2 (5.0 mg) at 4 °C with 
stirring. This solution was gradually warmed to room temperature. After 2 h, the 
solvent was removed under vacuum to yield 3.0 mg of nocarimidazol B 
diazomethane derivative (3). 1H NMR (CDCl3): δH 6.94 (H-2, s, 1H), 3.42 (3-NCH3, 
s, 3H), 2.84 (H-7, t, J =8.4 Hz, 2H), 1.68 (H-8, q, J =7.7, 2H), 1.26 (H-9, m, 2H), 
1.26 (H-11, m, 2H), 1.26 (H-12, m, 2H), 1.24 (H-13, m, 1H), 1.07 (H-10, m, 2H), 
1.05, 1.22 (H-14, m, 2H), 0.82 (H-15, t, J =8.4, 3H), 0.79 (H-16, d, J =7.0, 3H), 
EIMS m/z  266 [M]+ 
Nocarimidazole Iodomethane Derivative (4); A solution of 6.0 mg (0.024 mmol) of 
nocarimidazol B in 0.5 mL of DMF An appropriate amount of 0.167 mmol of 
Potassium carbonate (7 eq) was added and the whole was methylated with 0.5 mL 
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of CH3I. Then the mixture was heated to 60oC for 24 h to gave 4.0 mg of crude 
product (66% yield), which were purified by reversed-phase HPLC (Phenomenex 
Luna C-18 (2), 250×10 mm, 2.5 mL/min, 5 μm, 100 Å , UV = 254 nm) using an 
gradient solvent system of water and acetonitrile from 20% Acetonitrile to 100% 
Acetonitrile to afford a methyl nocarimidazol B (4, 1.5 mg) 1H NMR (CDCl3): δH 
8.76 (H-2, s, 1H), 3.95 (1-NCH3, s, 3H), 3.66 (4-NHCH3, s, 3H), 2.66 (H-7, t, J =7.2 
Hz, 2H), 1.64 (H-8, q, J =7.4, 2H), 1.29 (H-8, m, 2H), 1.26 (H-11, m, 2H), 1.26 (H-
12, m, 2H), 1.25 (H-13, m, 1H), 1.23 (H-9, m, 2H), 1.05, 1.23 (H-14, m, 2H), 1.07 
(H-10, m, 2H), 0.85-0.76 (H-15, H-16, m, 6H), EIMS m/z  280 [M]+ 
 
    2.3.5 Bioassay Procedures 
      2.3.5.1 Cytotoxicity Test 
 The cytotoxicity test was performed for two human cancer cell lines, A498 and 
ACHN renal cancer, according to a previously published method19 with 
modifications. The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin at 37°C in a 
humidified atmosphere incubator (5% CO2 in air). Wells with DMSO were used as 
negative controls, and temsirolimus, sunitinib and gemcitabine were used as positive 
controls 
 
      2.3.5.2 MIC Assay 
A following seven bacterial strains were used: four Gram-positive (Staphylococcus 
epidermidis ATCC 12228, Micrococcus lutes ATCC 9341, Bacillus subtilis ATCC 
6633, S. aureus ATCC 65381) and three Gram-negative (Escherichia coli ATCC 
11775, Salmonella typhimurium ATCC 14028, Klebsiella pneumonia ATCC 4352). 
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These bacteria were inoculated in Mueller-Hinton agar media for 24 h at 37°C. The 
bacterial colony was cultivated into a 15 mL round tube containing 6 mL of Mueller-
Hinton broth media at 37°C and 225 rpm for 24 h. Test compound (1) and a positive 
control (gentamicin) dissolved in DMSO were added 100 μL of each to 96-well 
microtiter plate having 50 μL of Mueller-Hinton broth in rest well. The samples were 
serially diluted and 50 μL of bacterial Mueller-Hinton broth media adjusted to 
concentration of 1/100 diluted McFarland 0.5% standard. The 96-well was incubated 
for 24 h at 37°C. After then, the minimum inhibitory concentration (MIC) values 
were determined as the concentration of compounds at transparent well which inhibit 
the growth of bacteria. 
 
      2.3.5.3 Acetylcholinesterase Inhibitory Assay 
The AChE inhibitory activity was measured using the modified method of Ellman et 
al. Briefly, a reaction mixture containing 140 μL of sodium phosphate buffer (pH 
8.0), 20 μL of the test sample solution, and 20 μL of AChE was incubated for 15 min 
at 25°C. Following the incubation, the reaction was initiated by adding 10 μL of 
dithiobisnitrobenzoate (DTNB) and 10 μL of ACh and incubated for 10 min at 25°C. 
The hydrolysis of ACh was monitored and quantified in a spectrophotometer at 412 
nm to measure the formation of DTNB with thiocholine released by the enzymatic 
hydrolysis of ACh. Donepezil hydrochloride (Santa Cruz Biotechnology) was used 
as a positive control. The 50% inhibitory concentration (IC50) of the donepezil 
hydrochloride was 0.02 ± 0.004 μM. All reactions were performed in triplicate on 
96-well plates and recorded using a VERSA max plate reader (Molecular Devices). 
The percentage of inhibition was calculated as (1 – S/E) × 100, where E and S are 
the enzyme activities with and without the sample. 
28 
Chapter 3. Marine Natural Products from Mudflat-
Derived Actinomycetes 
  3.1 Introduction 
Actinomycetes have been a promising source of bioactive natural compounds 
for several decades (Bérdy, 2005). Soil-derived actinomycetes have 
traditionally been the main source of bioactive natural products. In the 1980s, 
the first marine-derived actinomycete, Rhodococcus marinonascens, was 
described (Helmke & Weyland, 1984). Since then, marine sediments from 
beach sand to the deep sea bottom have been good environmental sources for 
isolating actinomycetes, which provide diverse bioactive secondary 
metabolites (Fenical & Jensen, 2006). Mudflats, also known as tidal flats, are 
intertidal zones with deposited mud, which create a unique ecological niche. 
This wetland is covered with salt water one to two times a day and is exposed 
to strong sunlight, which causes extreme environmental changes for the 
organisms living there. Despite these harsh environmental conditions, this 
zone is crowded with various microbial communities due to the rich nutrients 
available from the land and from the seawater. This unique ecological niche 
could also be an excellent environment for diverse bacterial species, including 
actinomycetes (Kim et al., 2004), a situation that often leads to unique 
chemical structures with diverse biological activities. Recently, our group 
reported that a Streptomyces sp. isolated from tidal flat sediments collected 
on Anmyeon Island, located on the west coast of Korea, produced 
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biologically active sesquiterpenoids with an indene moiety, anmindenols A 
and B (Lee et al., 2014). 
 
 
Figure 3.1 Sesquiterpenoids isolated from mudflat-drived actinomycetes 
 
 Actinomycete-derived natural products have not been examined extensively to 
combat neurodegenerative diseases, but specific efforts are ongoing. One of the 
diseases being studied is Alzheimer’s disease (AD), which deteriorates cognitive 
function. The most common molecular target for drugs that act on the symptoms of 
AD is acetylcholinesterase (AChE) (Parsons et al., 2013). ChE inhibitors block the 
AChE enzyme and prevent the neurotransmitter acetylcholine (ACh) from being 
broken down by AChE, thereby increasing the level of ACh at the synapse and the 
duration and action of ACh. Thus far, few compounds that exhibit AChE inhibitory 
activity, such as geranylphenazinediol (Ohlendorf et al., 2012), elaiomycins B and 
C (Kim et al., 201), N98-1272A (Zheng et al., 2007), and cyclophostin (Kurokawa 
et al., 1993), have been isolated from Streptomyces species. 
 
31 




  3.2 Results and Discussion 
 As part of our continued research into bioactive secondary metabolites from marine 
actinomycetes on the Korean peninsula, Streptomyces sp. 10A085 was isolated from 
a mudflat sediment sample. Chemical investigation of this strain yielded three new 
natural products, anithiactins A-D (1-4). Here, we present details of the isolation of 
anithiactins A-D and their biological activities in terms of AChE inhibition. 
 Anithiactins are members of the 2-phenylthiazole class of natural products. 
The representative natural products belonging to this class are aeruginoic acid 
(Yamada et al, 1970), aeruginol (Yang et al., 1993) and the pulicatins (Lin et 
al, 2010). In particular, the chemical structures of the anithiactins are closely 
related to those of aeruginoic acid and the pulicatins. Aeruginoic acid, a 
fluorescent natural product, was isolated from the culture medium of 
Pseudomonas aeruginosa and displayed antihypotensive activity (Imai et al., 
1973). The pulicatins, isolated from a cone snail (Conus pulicarius) associate 
Streptomyces sp., showed G protein-coupled receptor 5-HT2B inhibition 
activity in the micromolar range.8 These natural products possess an OH 
group at C-2, whereas anithiactins have an N-methyl group. This aniline 




Figure 3.3 Known 2-phenylthiazole class natural products 
 
    3.2.1 Structure Elucidation of Anithiactins 
      3.2.1.1. Anithiactin A (1) 
Anithiactin A (1) was obtained as a yellowish amorphous solid. The molecular 
formula of 1 was established as C12H12N2O2S based on high resolution MS data. The 
1H NMR spectrum displayed a 1, 2-disubstituted benzene ring moiety [H-3 (δH 6.77, 
d, J = 7.8 Hz), H-4 (δH 7.32, ddd, J =7.8, 7.8, 1.3 Hz), H-5 (δH 6.67, dd, J = 7.8, 7.8 
Hz), and H-6 (δH 7.63, dd, J = 7.8, 1.3 Hz)]. The 1H NMR spectrum also showed a 
downfield singlet proton H-4′ (δH 8.04, s), and N-methyl and O-methyl singlets [2-
NHMe (δH 3.01, s), 7′-OMe (δH 3.96, s)]. The HMBC correlations from the singlet 
proton H-4′ (δH 8.04, s) to carbons C-2′ (δC 170.1), C-5′ (δC 146.1) and C-7′ (δC 161.7) 
and the molecular formula of 1 allowed the construction of a thiazole ring moiety 
(Figure 3.4). The connection between the 1, 2-disubstituted benzene ring moiety and 
the thiazole ring moiety was achieved using HMBC correlations from the aromatic 
proton H-6 and the singlet proton H-4′ to C-2′. Lastly, the attachment of the N-methyl 
and the O-methyl groups at C-2 and C-7′, respectively, based on HMBC correlations 
from the N-methyl singlet to C-2 and the O-methyl singlet to C-7′ completed the 








Table 3.1 Physical and spectral properties of anithiactin A (1) 
Yellowish amorphous solid 
Molecular formula: C12H12N2O2S, 
HRFABMS: m/z 249.0698 [M+H]+ (calcd for 249.0698) 
IR (film) vmax: 3303, 3122, 1727, 1580, 1491, 1446, 1214, 1173, 1104, 906, 753, 738 cm-1 
UV (MeOH) λmax (log ε): 209 (5.07), 222 (4.78), 247 (4.31), 286 (4.05), 383 (4.10) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
1 
C, mult.b H (J in Hz) 
1 114.3, C  
2 147.5, C  
2-NHMe 29.8, CH3 3.01, S 
2-NH  8.43, br s 
3 111.1, CH 6.77, d (7.8) 
4 131.9, CH 7.32, ddd (7.8, 7.8, 1.3) 
5 115.0, CH 6.67, dd (7.8, 7.8) 
6 129.4, CH 7.63, dd (7.8, 1.3) 
2′ 170.1, C  
4′ 125.1, CH 8.04, s 
5′ 146.1, C  
7′ 161.7, C  
7′-OMe 52.3, CH3 3.96, s 
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.2. Anithiactin B (2) 
 The molecular formula of anithiactin B (2) was obtained as C11H11N3OS on the 
interpretation of the protonated molecule at m/z 234.0701 [M+H]+ in the HRFABMS 
data. The 1H NMR spectrum of anithiactin B (2) was very similar to that of 1 except 
for the absence of an O-methyl singlet and the presence of two singlet protons (δH 
5.73, δH 6.88). The analysis of the 2D NMR spectroscopic data and the molecular 
formula of 2 indicated that anithiactin B had an NH2 group at C-7′ instead of a methyl 
ester. The structure of 2 was also confirmed using X-ray crystallographic data 
(Figure 3.6). Slow evaporation of a concentrated solution of 2 in hexane and CHCl3 
mixture yielded yellow needles. 
 
 




Figure 3.6 X-ray crystal structure of anithiactin B (2) 
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Table 3.2 Physical and spectral properties of anithiactin B (2) 
Yellowish needle 
Molecular formula: C11H11N3OS, 
HRFABMS: m/z 234.0701 [M+H]+ (calcd for 234.0701) 
IR (film) vmax: 3415, 3321, 3193, 1650, 1609, 1581, 1485, 1367, 1215, 1175, 988, 804, 751 
cm-1 
UV (MeOH) λmax (log ε): 211 (4.67), 219 (4.41), 247 (3.91), 287 (3.67), 383 (3.70) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
2 
C, mult.b H (J in Hz) 
1 114.9, C  
2 147.3, C  
2-NHMe 30.2, CH3 3.00, d (5.0) 
2-NH  7.74, br s 
3 111.3, CH 6.77, d (7.8) 
4 132.2, CH 7.35, ddd (7.8, 7.8, 1.4) 
5 115.9, CH 6.71, dd (7.8, 7.8) 
6 130.0, CH 7.64, dd (7.8, 1.4) 
2′ 170.5, C  
4′ 122.9, CH 8.08 s 
5′ 149.2, C  
7′ 162.9, C  
7′-NH2  5.73, 6.88 br s 
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.3. Anithiactin C (3) 
 The 1H NMR spectrum of anithiactin C (3) was almost identical to that of anithiactin 
A (1) except for the absence of the O-methyl group. The molecular formula of 3 was 
established as C11H10N2O2S based on the HRFABMS data, indicating 3 had 14 Da 
less mass than anithiactin A. These data suggested that 3 had an OH group instead 
of an O-methyl group at C-7′. Interpretation of the 2D NMR spectroscopic data 
permitted the assignment of structure 3. 
 
 




Table 3.3 Physical and spectral properties of anithiactin C (3) 
Yellowish amorphous solid 
Molecular formula: C11H10N2O2S, 
HRFABMS: m/z 235.0543 [M+H]+ (calcd for 235.0541) 
IR (film) vmax: 3417, 2923, 1573, 1492, 1383, 1285, 1214, 1172, 750 cm-1 
UV (MeOH) λmax (log ε): 211 (4.56), 219 (4.30), 261 (3.63), 286 (3.57), 379 (3.57) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
3 
C, mult.b H (J in Hz) 
1 116.5, C  
2 148.8, C  
2-
NHMe 
29.9, CH3 2.84, s 
2-NH  4.51, br s 
3 112.1, CH 6.64, d (7.8) 
4 132.6, CH 7.14, ddd (7.8, 7.8, 1.3) 
5 116.1, CH 6.49, dd (7.8, 7.8) 
6 130.5, CH 7.50, dd (7.8, 1.3) 
2′ 170.3, C  
4′ 123.1, CH 7.83, s 
5′ 154.9, C  
7′ 170.2, C  
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.4. Anithiactin D (4) 
 The LRMS of anithiactin D was 423 and 445, which suggest 422 as molecular 
weight. The 1H NMR spectrum displayed a 1, 2-disubstituted benzene ring moiety 
[H-6″ (δH 7.32, d, J = 7.8 Hz), H-7″ (δH 7.04, dd, J = 7.8, 7.8 Hz), H-8″ (δH 6.94, dd, 
J = 7.8, 7.8 Hz), and H-9″ (δH 7.48, d, J = 7.8 Hz)]. The 1H NMR spectrum also 
showed a 1, 2, 4-trisubstituted benzene ring moiety [H-3 (δH 6.74, d, J = 7.8 Hz), H-
4 (δH 7.42, dd, J = 7.8, 1.3 Hz), and H-6 (δH 7.76, d, J = 1.3 Hz)]. The 1H NMR 
spectrum also showed downfield singlet protons H-4′ (δH 8.07), H-2″ (δH 7.27) and 
one N-methyl singlet [2-NHMe (δH 2.96, s)]. The upfield signals showed two 
methines [H-10″ (δH 4.27, d, J = 7.0 Hz) and H-11″ (δH 4.41, ddd, J = 7.0, 7.0, 4.2 
Hz)] and one methylene [H-12″a (δH 3.61, dd, J = 7.0, 4.2 Hz) and H-12″b (δH 3.48, 
dd, J = 7.0, 4.2 Hz)]. The HMBC correlations from singlet proton H-4′ (δH 8.07, s) 
to carbons C-2′ (δC 171.7), C-5′ (δC 150.6) and C-6′ (δC 165.6) allowed the 
construction of a thiazole ring moiety. The HMBC correlations from H-6 (δH 7.76, 
s) to carbons C-2 (δC 147.0), C-4 (δC 134.2), C-5 (δC 130.8) and C-2′ (δC 171.7) 
attached thiazole ring with 1, 2, 4-trisubstituted benzene ring. The HMBC 
correlations from singlet proton H-2″ (δH 7.27, s) to carbons C-3″ (δC 117.8), C-4″ 
(δC 128.2), C-5″ (δC 137.9) and C-6″ (δC 112.2) with 1, 2-disubstituted benzene ring 
allowed the construction of a indole moiety. The connection between the indole 
moiety and phenyl thiazole was achieved using HMBC correlations from the methine 
proton H-10″ to carbons C-4, C-5, C-4′, C3″ and C-4″. The COSY correlations from 
H-11″ (δH 4.41, ddd, J = 7.0, 7.0, 4.2 Hz) to H-10″ (δH 4.27, d, J = 7.0 Hz) and H-






Figure 3.8 COSY and key HMBC correlations of anithiactin D (4) 
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Table 3.4 Physical and spectral properties of anithiactin D (4) 
Yellowish amorphous solid 
Molecular formula: C22H22N4O3S (interpretation of NMR and LRMS data) 
LRMS: m/z 423 / 445 
1H and 13C NMR dataa (CD3OD) 
No. 
4 
C, mult.b H (J in Hz) 
1 115.4, C  
2 147.0, C  
2-NHMe 30.0, CH3 2.96, s 
3 112.0, CH 6.74, d (7.8) 
4 134.2, CH 7.42, dd (7.8, 1.3) 
5 130.8, C  
6 131.3, CH 7.76, d (1.3) 
2′ 171.7, C  
4′ 123.3, CH 8.07 
5′ 150.6, C  
6′ 165.6, C  
2″ 123.1, CH 7.27, s 
3″ 117.8, C  
4″ 128.2, C  
5″ 137.9, C  
6″ 112.2, CH 7.32, d (7.8) 
7″ 122.3, CH 7.04, dd (7.8, 7.8) 
8″ 119.5, CH 6.94, dd (7.8, 7.8) 
9″ 119.8, CH 7.48, d (7.8) 
10″ 45.6, CH 4.27, d (7.0) 
11″ 75.6, CH 4.41, ddd (7.0, 7.0, 4.2) 
12″ 66.2, CH2 3.61 d (7.0, 4.2) 
  3.48 d (7.0, 4.2) 
a 700 MHz for 1H NMR and 150 MHz for13C NMR. b Numbers of attached protons were determined by 




    3.2.2 Synthesis of Anithiactin A (1) 
 To further investigate the underlying biology of AChE inhibition using the 
anithiactins, a three -step synthetic route (Scheme 1) was developed for anithiactin 
A (1) using commercially available reagents. Thiobenzamide (6) was obtained from 
the sulfur substitution reaction of the anthranilamide (5) in 89% yield, which was 
then treated with bromopyruvate in dimethylformamide, a known thiazole ring 
formation reaction, to give thiazole 7 (Hoveyda et al., 2011). To achieve the selective 
N-monomethylation of 7, we first attempted to use common methylation reagents, 
such as methyl iodide, n-butyl lithium and sodium cyanoborohydride. These 
methylation reagents gave the N-dimethyl product of thiazole 7. Next, a solution of 
formaldehyde in dichloroethane and acetic acid was used as a mild methylation 
reagent for thiazole 7. The reaction mixture was stirred overnight, and sodium 
triacetoxy borohydride at 0°C was added. The mixture was left at room temperature 
for 2 h and yielded the N-monomethyl product (1) (Bonjouklian et al., 2004). The 
physical and spectroscopic data of the synthesized product were identical to the data 
for the natural product anithiactin A (1). 
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Scheme 3.1. Synthesis of anithiactin A (1) 
 
    3.2.3 Bioactivities of Anithiactins 
 A number of previous studies demonstrated that AChE inhibitory activity was 
improved by replacing a phenyl or oxazole with the thiazole moiety (Nagal et al., 
1995; Ronco et al., 2009). Recently, a thiazole containing AChE inhibitor, 
acotiamide (Acofide), was launched in Japan and is in preparation for phase III 
clinical trials in the EU (Nolan & Scott, 2013). Therefore, we examined the AChE 
inhibitory activities of anithiactins A-C (1-3) using the modified method of Ellman 
et al. (1961). Anithiactins A-C displayed AChE inhibitory effects with IC50 values 
of 63, 53, and 68 μM respectively. We also evaluated the cytotoxicity of the 
anithiactins against cancer cell lines. The three anithiactins did not show any 
significant cytotoxicity against A-498 and ACHN human cancer cell lines up to 200 




Figure 3.9 Acetylcholinesterase inhibitors containing thiazole moiety (Compound 




  3.3 Experimental 
    3.3.1 Instruments and Data Collection 
UV spectra were recorded in MeOH on a Scinco UVS-2100. The IR spectra were 
obtained using a Thermo Electron, Nicolet 5700 spectrometer. NMR spectra were 
obtained using Bruker Avance DPX-500 or DPX-600 spectrometers. CHCl3 (H 7.26; 
C 77.0) and MeOH (H 3.31; C 49.3) resonances were used as internal references. 
The HRFABMS were determined on a JEOL, JMS-600W spectrometer. The 
solvents used were EP grade products from Dae-Jeong & Metals Co., Korea. HPLC 
grade solvents were purchased from Burdick & Jackson Co. Medium-pressure liquid 
chromatography was performed on EM Science silica gel (230−400 mesh). TLC was 
performed using EM Science precoated silica gel plates (Merck 60 F254). The 
separation of extracts using an HPLC Waters 515 pump and a Waters 996 photodiode 
array detector was carried out using MG2 C18 (250 × 10 mm, 5 μm). The chemical 
reagents used for synthesis were purchased from Aldrich and TCI. All culture media 
were purchased from BD. 
 
    3.3.2 Microorganism Isolation and Fermentation 
 Streptomyces sp. 10A085 was obtained from marine sediments from Jaebu Island, 
GyeongGi-Do, South Korea in 2010. The sampled mud sediments were dried in air 
for 24 h on a clean bench and given a heat shock at 55 °C for 5 min to eliminate other 
bacteria. Aggregated clumps were lightly mortared using a glass rod and stamped 
onto various solid agar substrates. Some of the dried samples were suspended in 
sterilized seawater, and the diluted suspension was spread on variously prepared 
solid agar substrates using a disposable plastic rod. These crude plates were placed 
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in a 27 °C chamber and monitored for 1 to 3 months to obtain unique actinomycete-
like colonies. Strain 10A085 was picked from an ISP medium 4 agar plate containing 
white spores. The 16S gene was cloned using universal primers 27F and 1492R and 
showed 99% (1350/1357) similarity to Streptomyces sp. HV10 (accession no. 
KM881709). 
 
    3.3.3 Extraction and Compound Isolation 
 Strain 10A085 was cultured at 25 °C with shaking at 150 rpm in 24 Pyrex flasks, 
each containing 1 L of SYP medium (10 g soluble starch, 4 g yeast extract, and 2 g 
peptone dissolved in 1 L of 75% filtered natural seawater from Incheon, Korea). 
After 10 days, the broth was extracted twice using EtOAc, and the solvent was dried 
in vacuo to yield 2.6 g of extract. The extract (2.6 g) was separated using a silica 
column-equipped MPLC and step-gradient elution of MeOH in CH2Cl2 (0%, 1%, 
2%, 5%, 10%, 20%, 50%, 90% and 100%). Fraction 1 was further purified using 
reversed-phase HPLC (MG2 C18 
280 nm; CH3CN:H2O = 70:30) to obtain 1.0 mg of anithiactin A (1). Fraction 3 was 
also purified using the same column, eluting with 98% CH3CN in H2O to afford 
anithiactin B (2, 3.0 mg). Anithiactin C (3, 3.0 mg) was isolated from fraction 8 with 
the same isolation procedure used for anithiactin B. 
 
    3.3.4 X-ray Crystallographic Analyses 
 The single-crystal X-ray diffraction data of the compound was collected with a 
Bruker SMART APEX CCD detector employing graphite-monochromated Mo Kα 
radiation (λ = 0.71073 Å) at 273(2)K. The data collection and integration were 
performed using SMART (Madison, WI, 2000) and SAINT-Plus (Madison, WI, 
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2001). The structure was solved using direct methods and refined using full-matrix 
least-squares on F2 using SHELXTL (Madison, WI). All the non-hydrogen atoms 
were refined anisotropically, and hydrogen atoms were added to their geometrically 
ideal positions.  
Anithiactin B (2): yellow needle; C11H11N3OS, Mr = 233.30, monoclinic, a = 
15.1825(12) Å, b = 5.2022(4) Å, c = 14.7674(12) Å, α = 90°, β = 111.728(2)°, γ = 
90°, V = 1083.50(15) Å 3 , space group P2(1)/c, Z = 4, Dx = 1.430 mg/m3 , μ(Cu Kα) 
= 0.279 mm−1, and F(000) =488. Crystal dimensions: 0.18 × 0.14 × 0.12 mm3. 
Independent reflections: 2677 (Rint = 0.0825). The final R1 values were 0.0644, wR2 
= 0.1544 (I > 2σ(I)). CCDC number: 1022818. 
 
    3.3.5 Synthesis Procedures 
 Sulfur Substitution Reaction of Anthranilamide (5);  A solution of anthranilamide 
(5, 200 mg, 1.47 mmol) and the Lawesson reagent (320 mg, 0.8 mmol) in THF (10 
mL) was stirred under N2 at r.t. for 24 h. The reaction mixture was partitioned 
between EtOAc (15 mL) and 2 N HCl (15 mL). A saturated aqueous NaHCO3 
solution was added to the separated aqueous layer until pH 8 – 9 and extracted with 
EtOAc (2 × 20 mL). The combined organic layer was dried with MgSO4 and filtered. 
The solvent was evaporated in vacuo and the thiobenzamide (6) was obtained after 
silica gel column chromatography (n-Hexane:EtOAc = 3:1). 
Thiobenzamide (6): 200 mg (1.31 mmol, 89%), yellow amorphous solid; 1H NMR 
(700 MHz, CD3OD): δ ppm 6.67 (dd, J = 7.0, 7.0 Hz, 1 H), 6.78 (dd, J = 7.0, 1.2 Hz, 
1 H), 7.14 (ddd, J = 7.0, 7.0, 1.2 Hz, 1 H), 7.26 (dd, J = 7.0, 1.2 Hz, 1 H); 13C NMR 
(175 MHz, CD3OD): δ ppm 118.4, 118.9, 126.9, 128.2, 132.5, 147.8, 203.8; 
LRESIMS m/z 153 [M + H]+ 
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 Formation of Thiazole (7);  To a solution of thiobenzamide (6, 100 mg, 0.66 mmol) 
in DMF (10 mL) was added bromopyruvate (70 µL, 0.66 mmol). The mixture was 
stirred under N2 at 65 °C for 2 h. The reaction mixture was partitioned between 
EtOAc (20 mL) and saturated aqueous NH4Cl solution (20 mL). The aqueous layer 
was extracted with EtOAc (2 × 20 mL) and combined organic layer was dried with 
MgSO4 and filtered. The solvent was removed in vacuo and the thiazole (7) was 
obtained after silica gel column chromatography (nHexane:EtOAc = 3:1). 
Thiazole (7): 100 mg (0.42 mmol, 65%), pale yellow amorphous solid; 1H NMR (700 
MHz, CDCl3): δ ppm 3.94 (s, 3 H), 6.70 (dd, J = 7.0, 7.0 Hz, 1 H), 6.78 (d, J = 7.0 
Hz, 1 H), 7.19 (dd, J = 7.0, 7.0 Hz, 1 H), 7.59 (d, J = 7.0 Hz, 1 H), 8.05 (s, 1H); 13C 
NMR (175 MHz, CDCl3): δ ppm 55.3, 114.7, 116.8, 116.9, 125.2, 129.1, 131.4, 
145.9, 146.4, 161.7, 167.8; LRESIMS m/z 235 [M+H]+ 
 Monomethylation of Thiazole (7);  Add formaldehyde (10 mg, 0.33 mmol) to a 
mixture of thiazole (7, 40 mg, 0.17 mmol), acetic acid (1 mL) and 1, 2-
dichloroethane (10 mL). The reaction mixture was stirred overnight at r.t. and 
sodium triacetoxyborohydride (55 mg, 0.26 mmol) was added at 0°C. The reaction 
mixture was stirred for 2h at r.t. and partitioned between EtOAc (10 mL) and 
saturated aqueous NaHCO3 solution (20 mL). The aqueous layer was extracted with 
EtOAc (2 × 20 mL) and combined organic layer was dried with MgSO4 and filtered. 
The solvent was removed in vacuo and the anithiactin (1) was obtained after silica 
gel column chromatography (n-Hexane:EtOAc = 4:1). 
Anithiactin A (1): 18 mg (0.17 mmol, 43%), yellow amorphous solid; 1H NMR (700 
MHz, CDCl3): δ ppm 3.01 (d, J = 7.4 Hz, 3 H), 3.96 (s, 3 H), 6.66 (dd, J = 7.0, 7.0 
Hz, 1 H), 6.76 (d, J = 7.0 Hz, 1 H), 7.32 (dd, J = 7.0, 7.0 Hz, 1 H), 7.63 (d, J = 7.0 
Hz, 1 H), 8.04 (s, 1 H), 8.41 (br, 1 H); 13C NMR (175 MHz, CDCl3): δ ppm 29.8, 
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52.3, 111.0, 114.3, 115.0, 125.1, 129.44, 131.9, 146.1, 147.6, 161.7, 170.2; 
LRESIMS m/z 249 [M+H]+ 
 
    3.3.6 Bioassay Procedures 
      3.3.6.1 Cytotoxcity test 
 The cytotoxicity test was performed for two human cancer cell lines, A498 and 
ACHN renal cancer, according to a previously published method19 with 
modifications. The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin at 37°C in a 
humidified atmosphere incubator (5% CO2 in air). Wells with DMSO were used as 
negative controls, and temsirolimus, sunitinib and gemcitabine were used as positive 
controls 
 
      3.3.6.2 Acetylcholinesterase Inhibitory Assay  
 The AChE inhibitory activity was measured using the modified method of Ellman 
et al. Briefly, a reaction mixture containing 140 μL of sodium phosphate buffer (pH 
8.0), 20 μL of the test sample solution, and 20 μL of AChE was incubated for 15 min 
at 25°C. Following the incubation, the reaction was initiated by adding 10 μL of 
dithiobisnitrobenzoate (DTNB) and 10 μL of ACh and incubated for 10 min at 25°C. 
The hydrolysis of ACh was monitored and quantified in a spectrophotometer at 412 
nm to measure the formation of DTNB with thiocholine released by the enzymatic 
hydrolysis of ACh. Donepezil hydrochloride (Santa Cruz Biotechnology) was used 
as a positive control. The 50% inhibitory concentration (IC50) of the donepezil 
hydrochloride was 0.02 ± 0.004 μM. All reactions were performed in triplicate on 
96-well plates and recorded using a VERSA max plate reader (Molecular Devices). 
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The percentage of inhibition was calculated as (1 – S/E) × 100, where E and S are 
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A.1 Antibacterial Secosteroid from the Korean Sponge 
Irchinia sp. 
  A.1.1 Introduction 
 Marine Sponges are known as a source of structurally diverse natural products. This 
phylum of marine animal is possessing about 35% of reported marine natural 
products (Blunt et al., 2012). Many of the potent cytotoxins against cancer cell lines 
have been reported and some of them were developed as a lead of FDA approved 
drugs such as Cytosar-U® , and Halaven®  (Martins et al., 2014). The antibacterial 
activity of marine sponge-derived metabolites are also well known such as 
discorhabdin Z (Jeon et al., 2010), agelasine D (Hertiani et al., 2010), 7,20-
diisocyanoadociane (Wright et al., 2011), motualevic acid F (Keffer et al., 2009). In 
this regard, we have been investigated extracts of Korean marine sponges for the 
discovery of antibacterials. An extract of a Korean marine sponge in genus of Ircinia 
sp. showed antibacterial activities, and we continue the investigation of its bioactive 
constituents. 
 The genus Ircinia have been studied intensively and number of  biologically active 
natural products have been reported such as antibacterials (Manes & Crews, 1986; 
Faulkner, 1973), cytotoxin (Kondo et al., 1992), ichthyotoxin (De Rosa et al., 1996), 
analgesic compound (Cimino et al., 1972; De Pasquale et al., 1991), multidrug 
resistance modulator (Kawakami et al., 2001), thrombin inhibitor (Nakao et al, 1995), 
angiotensin converting enzyme/aldose reductase inhibitor (Alfano et al., 1979), and 
inosine monophosphate dehydrogenase inhibitor (Cafieri et al., 1972; De Rosa et al., 
1997). 
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 Also, this Ircinia sp. is well known for its possession of divers terpenes such as 
ircinin-1,7 variabilin (De Rosa et al., 1996), fasciculation (Cafieri et al, 1972), and 
strobilinin (Rothberg & Shubiak, 1975). In addition, hydroquinones (Cimino et al, 
1972a; Cimino et al. 1972b), chromans (Venkateswarlu & Reddy, 1994; Bifulco et 
al., 1995), and sterols (Venkateswarlu et al., 1996; Fu et al., 1999; Xu et al., 2008) 
have been reported. However, the organisms in Ircinia sp. was not reported for its 
secostrols. 
 Herein, we report the structure of an unprecedented secosterol with the 2-ene-1,4-
dione as well as its antibacterial activity. 
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  A.1.2 Results and Discussion 
    A.1.2.1 Structure Elucidation of 9,11-Secosterol (1) 
 The molecular formula of compound 1 was deduced as C27H44O5, based on the 
analysis of HRFABMS data (a pseudomolecular ion peak at m/z 449.3271 [M+H]+) 
and on the interpretation of 13C NMR data. The 1H NMR spectrum of 1 displayed an 
oxygenated methine proton [δ 4.04 (m)], an olefinic proton [δ 6.49 (br s)], and one 
downfielded methylene protons [δ 3.84 (m). 3.70 (m)]. The 1H NMR spectrum also 
showed two methyl singlets [δ 1.23, 0.70] and three methyl doublets [δ 0.97 (d, J = 
6.6 Hz), 0.88 (d, J = 2.3 Hz), 0.86 (d, J = 2.3 Hz)]. The 13C NMR and HSQC spectra 
revealed five methyl, ten methylene, six methine, and six fully-substituted carbons. 
The 27 carbons, five methyl protons, and an oxygenated methine proton are 
characteristic of a cholesterol carbon skeleton. Furthermore, 1H NMR signals of an 
olefinic proton δ 6.49 (s, 1H), oxymethylene protons [δ 3.70 (m, 1H), δ 3.84 (m, 
1H)], a downfield proton [δ 3.52 (dd, 1H, J = 11.0, 8.5 Hz)], and five methyls [δ 0.70 
(s, 3H), δ 1.23 (s, 3H), δ 0.97 (d, 3H, J = 6.6 Hz), δ 0.88 (d, 3H, J = 6.6 Hz), δ 0.86 
(d, 3H, J = 6.6 Hz)] suggested that 1 was a 9, 11-secosterol. 
 Interpretation of 2D NMR spectroscopic data permitted the structure assignment of 
1. Analysis of COSY spectroscopic data of 1 revealed three fragments (a, b, and c) 
as shown in Figure A.1.1. In addition, the carbon chemical shifts of C-6 (δ 197.5), 
C-7 (δ 134.4), C-8 (δ 152.1), and C-9 (δ 203.1), and the HMBC correlations from an 
olefinic proton H-7 to carbons C-6, C-8, and C-9 supported the construction of an 
ene-dione moiety. 
 The connectivity of A/B ring including the fragment a and the ene-dione moiety for 
1 was secured from HMBC correlations. The long-range HMBC correlations from 
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H-19 to carbons C-1, C-5, C-9, and C-10, and from H-4 to carbons C-2, C-5, and C-
10, and from H-7 to the carbon C-5 allowed the A/B ring connectivity. The fragments 
b and c were also connected from the interpretation of HMBC correlations. A two-
bond HMBC correlation from a methyl singlet proton H-18 to a carbon C-13, and 
three-bond HMBC correlations from H-18 to carbons C-12, C-17 permitted the C-
12/C-13/C-17 connectivity. Lastly, the establishment of C-8/C-14 attachment based 
on the interpretation of three-bond HMBC correlations from the olefinic proton H-7 
to a carbon C-14, and from the methyl singlet proton H-18 to a carbon C-14 allowed 
the completion of structure assignment of 1. (Figure A.1.2) 
 
 
Figure A.1.1 COSY and key HMBC correlations of 9,11-secosterol (1) 
 
 
Figure A.1.2 Chemical structure of 9,11-secosterol (1) 
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 The relative stereochemistry of the side chain and rings of 1 was identical to that of 
reported secosterols, which was determined by comparison with NMR data of known 
secosterols and by interpretation of NOESY correlations (Reddy et al., 1997; Lu & 
Faulkner, 1997). Briefly, NOESY correlations [H-7/H-14, H-14/H-12, H-12/H-21, 
H-18/H-20] were well corresponded to previously reported NOE correlations (Anta 
et al, 2002). The β-configuration of 3-hydroxy group at C-3 was defined from the 
coupling constants of H-4 (δ 2.16, dd, J = 13.1, 11.2 Hz) and NOESY correlations 
[H3/H4, H4 2.16)/H19]. (Figure A.1.3) 
 
 
Figure A.1.3 Key NOESY correlations observed for 9,11-secosterol (1) 
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Table A.1.1 Physical and spectral properties of 9,11-secosterol (1) 
Colorless needles 
Molecular formula: C27H44O5, 
HRFABMS: m/z 449.3271 [M+H]+ (calcd for 449.3275) 
IR (film) vmax: 3422, 2951, 2851, 1718, 1681, 1464, 1633 cm-1 
UV (MeOH) λmax (log ε): 274 (3.96) nm 
1H, 13C, COSY and HMBC NMR dataa (CDCl3) 
No. C, mb H, m, J (Hz) COSY HMBC (JCH = 10 Hz) 
1 25.9, t 1.77 m  
2.21 dt (11.2, 3.7) 
2 3, 5, 10, 19 
2 29.8, t 1.55 m  
2.00 m 
1, 3  
3 66.6, d 4.04 m 2, 4  
4 35.6, t 1.77 m  
2.16 dd (13.1, 11.2)  
3 2, 5, 10 
5 80.5, s    
6 197.5, s    
7 134.4, d 6.49, s   5, 6, 8, 9, 14  
8 152.1, s    
9 203.1, s    
10 52.1, s    
11 59.9, t 3.70 m;  
3.84 m  
12  
12 41.1, t 1.11 m 
1.73 m 
11  
13 47.5, s    
14 43.9, d 3.52 dd (11.0, 8.5) 15 7, 8, 9, 12, 13, 15, 18 
15 26.3, t 1.75 m  
1.84 m 
14, 16  
16 26.6, t 1.68 m  
1.75 m 
15, 17  
17 50.1, d 1.73 m 16, 20  
18 17.7, q 0.70 s  12, 13, 14, 17  
19 20.6, q 1.23 s  1, 5, 9, 10 
20 34.5, d 1.41 m 17, 21, 22  
21 18.8, q 0.97 d (6.6) 20 17, 20, 22 
22 35.6, t 0.99 m  
1.35 m 
20, 23 24 
23 24.4, t 1.15 m 
1.35 m 
22, 24  
24 39.4, t 1.13 m 
1.15 m 
23, 25  
25 27.9, d 1.51 m 24, 26, 27 23 
26 22.5, q 0.86 d (6.6) 25 24, 25, 27,  
27 22.7, q 0.88 d (6.6) 25 24, 25, 26 
5-OH  2.36 br s   
 a 600 MHz for 1H NMR and 150 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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    A.1.2.2 Antibacterial Activity of Secosterol  
 Compound 1 was evaluated for antibacterial activity against seven pathogenic 
strains. (Table A.1.2) Compound 1 displayed the most potent activity on 
Micrococcus lutes ATCC 9341 and also showed the moderate activity against 
Staphylococcus epidermidis ATCC 12228 and Bacillus subtilis ATCC 6633 with 
MIC values of 3.1, 25 and 25 μg/mL, respectively. Meanwhile, 1 did not show any 
activity against gram negative strains include Escherichia coli ATCC 11775, 
Salmonella typhimurium ATCC 14028 and Klebsiella pneumonia ATCC 4352 up to 
200 μg/mL. Interestingly, growth of one of the gram positive strain Staphylococcus 
aureus ATCC 65381 was not inhibited up to 200 μg/mL. 
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Table A.1.2 Antibacterial activity of 9,11-secosterol (1) 
Strain 1a Gentamicin a 
Staphylococcus epidermidis ATCC 12228 25 0.2 
Micrococcus lutes ATCC 9341      3.1 3.1 
Bacillus subtilis ATCC 6633 25 0.2 
S. aureus ATCC 65381 >200 0.2 
Escherichia coli ATCC 11775 >200 0.8 
Salmonella typhimurium ATCC 14028 >200 1.6 
Klebsiella pneumonia ATCC 4352 >200 0.8 




  A.1.3 Experimental 
    A.1.3.1 Instruments and Data Collection 
 The optical rotation was measured using a Rudolph Research Autopol III 
polarimeter with a 5 cm cell. The UV spectrum was recorded in a Scinco UVS-2100 
with a path length of 1 cm. Infrared spectra were recorded on a Thermo Electron 
Corporation spectrometer. NMR spectral spectroscopic data were obtained using 
Bruker Avance 600 MHz spectrometer [CDCl3 (δH 7.26; δC 77.0) was used as an 
internal standard]. HRFABMS data were measured on a JEOL, JMS-AX505WA 
mass spectrometer. 
 
    A.1.3.2 Animal Material 
The genus Ircinia sponge was collected by scuba diving at Yeongdeok-Gun in the 
East Sea. The sample was frozen immediately after collection with dry ice and stored 
in refrigerator at -20 °C before extraction.  
 
    A.1.3.3 Extraction and Isolation 
 The wet animal (3 kg) was extracted three times with 50% methanol (MeOH) in 
dichloromethane. These extracts were concentrated and partitioned three times 
between hexanes and MeOH. Then the MeOH-soluble layer was partitioned three 
times between ethylacetate (EtOAc) and water. The water-soluble fraction was 
further extracted thrice with n-butanol. The EtOAc-soluble layer (7.0 g) was 
subjected to silica flash column chromatography using step-gradient elution of 
EtOAc in hexanes (0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 
100%) to afford seven fractions (Fr 1-Fr 11). Fr 5 (68.3 mg), which contained the 
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mixture of 1, was further purified by reversed-phase HPLC (Polar-RP, 250 × 10 mm, 
5 μm, 80 Å, 2.5 mL/min, UV detection = 210 nm), eluting with 70% acetonitrile in 
H2O to afford compound 1 (2.7 mg), as colorless needles. 
 
    A.1.3.4 MIC Bioassay Procedures 
 The six microorganisms were obtained from the stock culture collection at the 
American Type Culture Collection (Maryland): The antibacterial activity was 
determined by the 2-fold microtiter broth dilution method (Wiegand & Hilpert, 
2008). Dilutions of the test compounds dissolved in DMSO were added to each well 
of a 96-well microtiter plate containing a fixed volume of Mueller Hilton broth (final 
0.64% DMSO). Each well was inoculated with an overnight culture of bacteria (5 × 
105 cfu/mL), and the plate was incubated at 37 °C for 24 h. The minimum inhibitory 
concentration (MIC) was taken as the concentration at which no growth was 
observed.
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A.2 NMR spectra of 9,11-Secosterol A 
 
Figure A.2.1 1H NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.2 13C NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 150 MHz) 
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Figure A.2.3  COSY NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.4  HSQC Spectrum of 9,11-Secosterol A 
 (CDCl3, 600 MHz) 
 
76 
Figure A.2.5  HMBC NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.6  NOESY NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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B.1 NMR Spectra of Nocrimidazoles A and B 80 














B.1 NMR Spectra of Nocrimidazoles A and B 
 
Figure B.1.1 1H NMR Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.2 13C NMR Spectrum of Nocarimidazol A (1) 
(CDCl3, 125 MHz) 
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Figure B.1.3   COSY Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.4 HSQC Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.5 HMBC Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.6 1H NMR Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.7 13C NMR Spectrum of Nocarimidazol B (2) 
(CDCl3, 125 MHz) 
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Figure B.1.8 COSY Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.9 HSQC Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.10 HMBC Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.11 1H NMR Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.12 COSY Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.13 HSQC Spectrum of Nocarimidazole B 




Figure B.1.14 HMBC Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.15 1H NMR Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.16 COSY Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.17 HSQC Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.18 HMBC Spectrum of Nocarimidazole B 












Figure B.1.3 COSY Spectrum of Nocarimidazol A (1) (CDCl3, 500 MHz)  
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Figure B.1.16 COSY Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.17 HSQC Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.18 HMBC Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
 
100 
B.2 NMR Spectra of Anithiactins A-D 
 
Figure B.2.1 1H NMR  spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.2 13C NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.3 COSY spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.4 HSQC NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.5 HMBC NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.6 1H NMR spectrum of Anithiactin B  
(CDCl3, 600 MHz) 
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Figure B.2.7 13C NMR spectrum of Anithiactin B  
(CDCl3, 600 MHz) 
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Figure B.2.8 1H NMR spectrum of Anithiactin C  
(CDCl3, 600 MHz) 
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Figure B.2.9 13C NMR spectrum of Anithiactin C  
(CDCl3, 600 MHz) 
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Figure B.2.10 1H NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.11 COSY NMR Spectrum of Anithiactin D 
(CD3OD, 700 MHz) 
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Figure B.2.12 HSQC NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.13 HMBC NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.14 1H NMR spectrum of synthetic intermediate 6 
(CDCl3, 600 MHz) 
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Figure B.2.15 13C NMR spectrum of synthetic intermediate 6 




Figure B.2.16 1H NMR spectrum of synthetic intermediate 7 
(CDCl3, 600 MHz) 
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Figure B.2.17 13C NMR spectrum of synthetic intermediate 7 
(CDCl3, 600 MHz) 
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Figure B.2.18 1H NMR spectrum of synthetic Anithiactin A 
(CDCl3, 600 MHz) 
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Figure B.2.19 13C NMR spectrum of synthetic Anithiactin A  






























Figure B.2.7 13C NMR spectrum of Anithiactin B (CDCl3, 600 MHz) 
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Figure B.2.10 1H NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.11 COSY NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.12 HSQC NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.14 1H NMR spectrum of synthetic intermediate 6 (CDCl3, 600 MHz) 
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Figure B.2.15 13C NMR spectrum of synthetic intermediate 6 (CDCl3, 600 MHz) 
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Figure B.2.16 1H NMR spectrum of synthetic intermediate 7 (CDCl3, 600 MHz) 
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Figure B.2.17 13C NMR spectrum of synthetic intermediate 7 (CDCl3, 600 MHz) 
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Figure B.2.18 1H NMR spectrum of synthetic Anithiactin A (CDCl3, 600 MHz) 
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 해양천연물은 원천생물의 다양성에 기반한 신약후보물질의 새로운 
공급원으로 각광받고 있다. 스쿠버다이빙이나 유인잠수정과 같은 기술의 
발전에 힘입어 관심이 더해지고 있으며, 현재 8 종의 해양신약이 개발되었다. 
대부분의 해양신약은 해양무척추동물로부터 분리된 해양천연물에 기반하여 
개발되었으나, 최근에 들어 실제적인 생산자가 해양미생물인 것이 알려지게 
되었다. 이 연구에서는 다양한 해양환경에서 분리된 방선균에서 신규한 
생리활성 해양천연물을 분리하였다. 
 미국 캘리포니아 연안의 퇴적물에서 분리한 Nocardiopsis sp. 
CNQ115 에서 2 개의 새로운 이미다졸 천연물인 nocarimidazole A 와 B 를 
분리하였다. Nocarimidazole A 와 B 의 화학구조를 NMR 을 이용하여 
결정하였다. 항균활성과 항암활성을 확인하였으나, 주목할만하지 않다. 
서해의 갯벌에서 Streptomyces sp. 10A085 를 분리하여 화학 조성물을 
분석하였다. 새로운 티아졸 천연물 anithiactin A – D 를 분리하여 NMR 을 
이용하여 화학구조를 결정하였다. Anithiactin B 는 X-ray 결정구조분석을 
같이 수행하였다. Anithiactin A – C 는 acetylcholinesterase 를 저해하는 
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 Marine natural products are emerging source as an attractive drug pipeline based on 
its enormous biological diversity of origin. Technical advances like scuba diving, 
manned submarine boosted the interest to the marine natural products three decades 
ago and there are eight approved marine drugs now. Most of the approved drugs are 
based on marine natural products isolated from marine invertebrates, but recent study 
suggest that most of them are produced by microorganisms. In this study, 
actinomycetes were isolated from marine envirionments and investigated to discover 
a novel and bioactive marine natural products.  
 A chemical investigation of the actinomycetes, Nocardiopsis sp. CNQ115 isolated 
from marine sediment collected off the coast of southern California resulted in the 
isolation of two novel imidazole natural compounds nocarimidazoles A and B. The 
chemical structures of nocarimidazoles A and B were determined by interpretation 
of NMR data analyses. No significant antibacterial or cytotoxic activities were 
observed. Investigation of the chemical components of a Streptomyces sp. 10A085 
isolated from mudflat sediments collected on the southern coast of the Korean 
peninsula led to isolation of four new compounds, anithiactins A – D. The chemical 
structures of anithiactins were determined by interpretation of NMR data analyses, 
while the chemical structure of anithiactin B was established from a combination of 
NMR spectroscopic and crystallographic data analysis. Anithiactins A – C displayed 
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Chapter 1. Marine Natural Products as a New 
Pharmaceutical Pipeline 
  1.1 History of Natural Products as a Source for Drug 
Development 
 From old days, natural products have been used as a drug source. Before the modern 
age, natural products were used as a form of extract or plant materials. The oldest 
written record of medicinal plant was shown on the clay slab at Sumeria 
approximately 5,000 years ago which described 12 recipes for drug preparation from 
more than 250 different plants (Kelly, 2009). In China, medical usage of Rhei 
rhisoma (rhubarb), camphor, Theae folium (tea tree), ginseng, cinnamon bark, 
ephedra and many other medicinal plants were known since 2,500 BC, and these 
plant are still widely used over eastern and southern Asia (Bottcher, 1965; Wiart, 
2006). After that, all through the history of mankind, continuous efforts to look for 
the healings were enormous and results were pass throughout the millennia 
(Petrovska, 2012).  
 After the advance of the science and technology in modern centuries, some of these 
medicinal plant become medicine after extraction, isolation and quantification. This 
technical improvement resulted in the development of many drugs such as khellin, 
metformin and verapamil. The khellin was isolated from plant Ammi visnaga Lamk 
and used as a bronchodilator. Efforts to reduce the side effects of khellin led to the 
development of chromolyn (used in the form of sodium chromoglycate). The 
galegine was isolated from the plant Galega officinalis L. as a major active 
ingredient of anti-hyperglycemia. The metformin was developed from galegine with 
2 
its main chemical structure maintained. The papaverine isolated from Papaver 
somniferum was advanced to verapamil to treat hypertension (Farbricant & 
Farnsworth, 2001). This medicinal plant is also well-known as a source of morphine 
and codeine (Buss & Waigh, 1995).  
 
 
Figure 1.1 Drugs developed from medicinal plants 
 
 However, the most famous example of medicinal plant derived medicine would be 
the antimalarial drugs development. First generation antimalarial drugs, such as 
chloroquine and mefloquine, were developed from quinine which was isolated from 
the bark of Cinchona sp. This plant extracts was used to treat fevers around the 
Amazon region traditionally. Spread of quinine-class resistance malaria led to the 
2 
discovery of artemisinin isolated from the plant Artemisia annua and the 
development of artemisinin class antimalarial drugs. This plant has been used to treat 
fevers in China for a long time (Wongsrichanalai et al., 2002). Artemisinin class 
drugs are deployed to combat malaria all across the world, even though its 
mechanism of action not clear (O'Neill & Posner, 2004; O'Neill et al., 2010; Wang 
et al. 2010). 
 
 
Figure 1.2 Antimararial drugs developed from medicinal plants 
  
 Likewise, using natural products as drug lead was deployed as useful tactics to 
combat other disease includes anticancer (Gueritte et al., 2005; Roussi et al., 2012) 
and antihypertensive (Cordell & Colyard, 2012). The analysis of the sources of small 
4 
molecule shows this trend clearly. Figure 1.3 is showing classified new drugs from 
1981 to 2010 based on its origin as synthetic (S) or natural product (N). It revealed 
that two thirds of the small molecules are natural products or natural products 
inspired. Only one third can be categorized as truly synthetic (Newman & Cragg, 
2012). Conclusively, natural products are major pipelines for developing drugs now 
and then (Cragg & Newman, 2013). 
 
 
Figure 1.3 Sources of drugs [N (an unmodified natural product), NB (a natural 
product botanical), ND (a modified natural product), S (a synthetic compound with 
no natural product conception), S*, S*/NM (a synthetic compound with a natural 
product pharmacophore; /NM indicating competitive inhibition), S/NM (a synthetic 
compound showing competitive inhibition of the natural product substrate)] (Cragg 
& Newman, 2013) 
 
  1.2 Marine Natural Products as a New Pharmaceutical Pipeline 
    1.2.1 Novelty of Marine Natural Products 
 Unlike its counter parts, marine resources were not used much as a medicinal 
sources for long time. Before scuba diving technique spread widely, collection of 
marine organisms under the water surface was very limited to specifically trained 
5 
professionals. Recent introduction of various technical advances like scuba, 
dredging, manned submarine and remotely operated vehicles gives more chance to 
address the marine resources. And this makes marine resources as a more attractive 
drug discovery pipeline. Currently, more than 30,000 marine natural products were 
reported and number is increasing (Blunt & Munro, 2008). 
 The most interesting character of the marine natural product is from biodiversity of 
marine organisms. For examples, there is only 1 terrestrial exclusive phylum among 
the 33 animal phyla. On the other hand, there are 15 of marine exclusive phyla and 
5 of the rest phyla have more than 95% of their species in marine (Margulis & 
Schwarts, 1988). This enormous number of marine animal species and phyla may 
due to the oldness and wideness of the ocean environment then terrestrial one. As 
terrestrial organisms are descendants of marine life and 70% of the earth surface is 





Figure 1.4 Number of estimated species of animal phyla in terrestrial and marine 
environment (Margulis & Schwarts, 1988, modified) 
 
 It is clear that more number of the species gives more chance to discover novel 
chemical structures. One of the Chinese chemistry group quantified the novelty of 
marine natural products (Kong et al., 2010). They categorized the known natural 
products from Dictionary of Natural Products and Dictionary of Marine Natural 
Products to the each of the specific ‘scaffolds’ which are defined as the contiguous 
ring systems with chains that link them. This scaffold analysis gave that there are 
163,089 terrestrial natural products using 25,289 scaffolds and 31,772 marine natural 
products using 5276 scaffolds. And more than 70% of marine scaffolds are using 


























































































































































































































































































Figure 1.5 Number of scaffolds accord with number of marine natural products 
(Kong et al., 2010) 
 
    1.2.2 Marine Drugs on the Market 
 There are eight Food and Drug Administration (FDA) and European Medicines 
Agency (EMEA) approved drugs (Meyer, 2014). The four of marketed drugs are 
used to treat cancer (Adcetris, Cytoser-U, Halaven, Yondelis), two for virus 
(Carragelose, Vira-A) and each of one for hypertriglyceridemia and neuropathic pain 
(Lovaza and Prialt). Three of these are employed to drug as natural product itself 
(Prialt, Yondelis, Carragelos) and others took modifications to solve the supply and 
ADMET properties problems. Regarding origin of the drugs, six of marine drugs 
were obtained from marine invertebrates like tunicate, sea hare, marine snail and 




Figure 1.6 Chemical structures of marine drugs on the market divided by 
therapeutic area (Martins et al., 2014 modified) 
 
 Marine drug pipelines is listed with nine more drug candidates under clinical trials 




Table 1.1 The marine drugs on market (Martins et al., 2014) 
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 Marine invertebrates are major supply for the marine drugs. It is because the many 
of marine natural products were obtained from marine invertebrates (Hu et al., 2011). 
(Figure 1.7) Within the marine invertebrate, sponge and coral were the main sources 
for the marine natural products. These animals are taking unique ecological roles to 
support the diversity of marine ecosystem. Coral reef are supporting up to 40% of 
all fish species while taking only 0.1% of ocean area around the tropical zone (Moyle 
& Cech, 2003). Sponges inhibit all around the ocean from polar area to the deep 
ocean trench bottom and associated with a wide variety of microorganisms (Taylor 
et al., 2007). It is known that from half to 80% of sponge weight is considered be 
that of associated bacteria. Both of these animals are filter-feeder, and providing 
physical shelters to around environment. However, the fact that marine invertebrates 
are main source of the marine drug is one of the main obstacle to overcome for the 
development of marine drugs that industrial scale cultivation technique for the most 







Figure 1.7 Temporal trends in the number of novel compounds isolated from 
different marine organisms between 1985 and 2008. [▲, marine invertebrate; ■, 
marine algae; ◆, Marine microorganisms (including phytoplankton).] (Hu et al. 
2011) 
 
    1.2.3 Major Hurdle of Marine Natural Products derived Drug Discovery 
 As described ahead, marine natural products have potentials as attractive drug 
pipeline and are taking more and more interests. However, there are several problems 
to overcome.  First of all, availability problems are still not neglectable. Despite of 
the introduction of many advanced methods, marine resource is not much close 
enough. Average depth of the open ocean is more than four thousand m, but general 
scuba technique allow us to only 40 m deep. Even with the most latest diving 
technique with atmospheric diving suit, depth reach is less than 700 m. The dredging 
is not considered these days for it is not eco-friendly and it is too much random 
sampling method. The budget for manned submarine is not available for most of the 
research group and even for the big pharmaceutical company. Recent introduce of 
12 
remotely operated vehicles can be a good alternative for most of the collection 
methods.  
 Second problem is biodiversity itself. As describe above, estimated number of 
marine organism is enormous. But there is not enough research infra to support that 
research. For example, sponge is one of the major source for the marine natural 
products for several decades, but convenient molecular level identification method 
like 16S RNA sequencing of microorganisms for this phylum is still under 
construction (Vargas et al., 2012). To have the desired result from this enormous 
resource, we need to set specific strategy considering ecological back ground and 
marine taxonomy.  
 Third and most important problem is supply. This issue can link with first addressed 
availability problem. As described above, most of the marine drugs were developed 
from invertebrate derived marine natural products. And most of those marine drug 
on market was 20 to 40 year after the first report of the natural products. It is mainly 
because of the supply problem that most of the industrial scale culture technique for 
marine invertebrate are not available yet. Those years are more than couple of 
decades longer than common process from terrestrial natural products. Most of these 
time gap used on the establishment of synthetic method for marine natural products 
supply. For example, Taxol was notorious for its supply problem. At early stage of 
discovery, 10 g of Taxol was isolated from 1,200 kg of Taxus brevifolia bark 
(Goodman & Walsh, 2001). Yield was low, but it was possible to do it. But it is not 
possible for marine natural products. There is no detailed research database of 
distribution of marine organisms as the forestry, also there is no industrial 
background to collect the marine organisms like the timber industry. 
13 
 Yondelis is good example of marine drugs which solve the supply problem with 
creative way. It was first isolated from tunicate Ecteinascidai turbinate (sea squirt) 
and elucidated in 1984 (Rinehart, 2000). At the early stage of discovery, it was 
supplied from sea squirt at extremely low yield. Based on its anticancer activity and 
novel chemical structure, many synthetic preparation methods were developed to 
meet the requirement of this drug for clinical trials. But break-through was on other 
way. The Spanish pharmaceutical venture company PharmaMar devised 
semisynthetic process from Safracin B, which was obtained from bacterium 
Pseudomonas fluorescens by fermentation. This intuition from Yondelis with other 
recent discovery suggest that actual producer of most current marine drug from 
marine invertebrates are symbiotic microorganisms (Gerwick & Moore, 2012). This 
also emphasize the importance of marine microorganisms as attractive drug 
discovery pipeline.  
 
 
Figure 1.8 Supply of yondelis (Cuevas & Francesch, 2009) 
 
 In this study, sponge and marine microorganisms were screened to discover novel 
natural products. Sponge was screening target as the traditional marine natural 
products source. Marine microorganisms from bottom sediment were isolated and 
13 
screened. Mudflat was selected for new source of marine microorganisms, based on 
its environmental uniqueness, and isolated microorganisms were screened. Obtained 




Chapter 2. Marine Natural Products from Sediment-
Derived Actinomycetes 
  2.1 Introduction 
 Actinomycetes are the most economically and biotechnologically valuable 
prokaryotes due to the discovery of wide range of bioactive secondary metabolites, 
such as antibiotics, antitumor agents, and immunosuppressive agents (Ravikumar et 
al, 2011). More than 15,000 bioactive molecules were produced by these microbes 
including many that are used as drugs today. As the soil-derived microorganisms 
have been intensively investigated for discovering therapeutically important 
molecules over a half century (Fenical, 1993), the frequency of new compounds 
discovery has been decreased. Therefore, an unexplored environment needs to be 
searched for isolating different microorganisms found in terrestrial environments. 
Recently, microorganisms isolated from the marine environments including the deep 
sea sediments and marine organisms, have been considered as a good source for 
exploring new natural products (Takami et al., 1997). In particular, marine 
actinomycetes have different characteristics from those of terrestrial counterparts 
that produced unprecedentedly secondary metabolites with diverse biological 




  2.2 Results and Discussion 
    2.2.1 Structure Elucidation of Nocarimidazoles from CNQ115 
 As part of our ongoing research to discover new bioactive compounds from marine-
derived actinomycetes, strain CNQ115, identified as Nocardiopsis sp. from marine 
sediments collected off the coast of southern California was investigated. The genus 
Nocardiopsis has been shown to be phylogenetically coherent and to represent a 
distinct lineage within the order Actinomycetales (Rainey et al., 1996). Nocardiopsis 
strains are ubiquitous in the environment and are frequently isolated from habitats 
with moderate to high salt concentrations such as saline soils, marine sediments, and 
salterns (Sabry et al., 2004). The strains of Nocardiopsis have also been reported to 
produce a variety of biologically active agents including the cytotoxic antifungal 
antibiotic kalafungin (Bergy, 1968), the antibiotic 3-trehalosamine (Dolak et al., 
1980), the protein kinase C inhibitor methylpendolmycin, and a staurosporine-like 
inhibitor of a cyclic AMP-dependent protein kinase (Peltola et al., 2001). LC-MS 
guided fractionations has led to two new natural products, nocarimidazols A (1) and 
B (2). Herein, we report the isolation and structure characterization of 
nocarimidazols A and B. 
 Imidazole derivatives were intensively studied for its pharmacological properties on 
various range of biological activities like analgesic and anti-inflammatory (Suzuki 
et al., 1992), anti-fungal (Johnson et al., 1999; Brewer et al., 1987) and anti-viral 
(Sharma et al., 2009). And many of prescription drugs have imidazole as a key 
pharmacophore (Zhang et al., 2014). Dacarbazine, well-known skin cancer and 
Hodgkin disease drug (Eggermont & Kirkwood, 2004), shares key chemical 
structure with nocarimidazoles, having carboxylic carbon and additional nitrogen at 
17 
4 and 5 position of imidazole ring. Also, many natural products with imidazole 
moiety have been reported (Jin, 2011). But, natural products which have 4-
carboxylic carbon with imidazole ring is very rare. And imidazole natural products 
with 4-carboxylic carbon and 5-amine group is not reported yet. 
 
 
Figure 2.1 Imidazole-based anticancer drugs (Eggermont & Kirkwood, 2004) 
 
     2.2.1.1 Nocarimidazole A (1) 
Actinomycete strain CNQ115, obtained from marine sediment sample collected off 
the coast of southern California, at a depth of 51 m, required seawater for growth. 
This strain shares 99.3% 16S rRNA gene sequence identity with its nearest neighbor, 
Nocardiopsis sp. The strain was cultured at 25 °C by rotary shaking in 8 replicate 
2.5-L Ultra Yield Flasks each containing 1 L of the medium for seven days. The 
broth was extracted with EtOAc and evaporated under reduced pressure to yield an 
18 
extract, which was subjected to flash chromatography followed by HPLC to afford 
pure samples of nocarimidazols A (1) and B (2). 
Nocarimidazols A (1) was obtained as a red amorphous solid. Its molecular formula 
was established as C13H23N3O based on HRESIMS (obsd [M + H]+ at m/z 238.1918), 
implying 4 degrees of unsaturation. The UV spectrum of 1 displayed absorption 
bands at 300 nm, indicating the presence of a significant chromophore in the 
molecule. The IR spectrum of 1 showed the presence of a primary amine (3433 and 
1640 cm-1) and an α, β-unsaturated carbonyl group at 1678 cm-1. Two substructures, 
a linear aliphatic chain and a imidazole moiety, were assigned by analyses of 1H, 13C, 
COSY, HSQC, and HMBC NMR spectroscopic data recorded in CDCl3 (Tables 2.1). 
The 1H NMR spectrum of 1 displayed a downfield singlet proton [(δH 7.80, s)]. The 
presence of alkyl chain moiety was suggested by a methyl doublet integrating for six 
hydrogens [δH 0.82, (d, J = 6.6 Hz)] and overlapping methylene proton signals [δH 
1.03 - 1.32, (m)] and one methine proton [δH 1.46, (m)] and two downfield methylene 
proton [δH 1.62 (q, J =7.4 Hz), 2.68 (t, J = 7.4 Hz)]. The COSY cross peaks of H3-
14 and H3-15 to H-13 indicated that these methyls were coupled to a methine proton 
(Table 2.1). The terminal gem dimethyl protons (H3-14 and H3-15) at δH 0.82, which 
showed HMBC correlations to C-13 (δC 27.9), and to C-12 (δC 38.9). The proton 
signal (δH 1.11) derived from H2-12 showed a HMBC correlation to C-11 (δC 27.2). 
These NMR data established a 2-methylbutane unit.  
The proton signal (δH 2.68) derived from H2-7 showed a COSY correlation to an 
aliphatic methylene proton signal at δH 1.62 (H2-8), which in turn showed a COSY 
correlation to another aliphatic methylene proton signal at δH 1.29 (H2-9). The proton 
signal (δH 2.68) derived from H2-7 also showed HMBC correlations to a carbonyl 
C-6 (δC 190.9). These NMR data established a pentanone unit. 
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The alkyl chain moiety was final established by HMBC correlation from the 
methylene protons H2-11 to the carbons C-9. The HMBC correlations from the 
singlet proton H-2 (δH 7.80, s) to carbons C-4 (δC 146.9) and C-5 (δC 111.7) and the 
molecular formula of 1 allowed the construction of a imidazole ring moiety. Lastly, 
the connection between the alkyl chain moiety and the imidazole ring moiety was 
achieved by the long range HMBC correlations from an olefinic proton H-2 to 
carbonyl carbon C-6 allowed the assignment of nocarimidazols A to be completed, 
as shown in Figure 2.2. 
 
 








Table 2.1 Physical and spectral properties of nocarimidazole A (1) 
Red amorphous solid 
Molecular formula: C13H23N3O, 
HRFABMS: m/z 238.1918 [M+H]+ (calcd for 238.1919) 
IR (KBr) vmax: 3433, 3054, 2928, 2360, 1678, 1640, 1384, 1265, 1201, 1140, 839, 749 cm-1 
1H and 13C NMR dataa (CDCl3) 
 
No. 
              1 
C, mult.b H (J in Hz) 
2 130.2, CH 7.80, s 









2.68, t (J = 7.4) 
8 24.1, CH2 1.62, q (J = 7.4) 
9 29.7, CH2 1.29, m 
10 38.8, CH2 1.22, m 
11 27.2, CH2 1.24, m 
12 38.9, CH2 1.11, m 
13 27.9, CH 1.47 dp (J = 13.1, 6.6) 
14 22.5, CH3 0.82, d (J = 6.6) 
15 22.5, CH3 0.82, d (J = 6.6) 
a 500 MHz for 1H NMR and 125 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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      2.2.1.2 Nocarimidazole B (2) 
Nocarimidazols B (2) was obtained as a red amorphous solid. Its molecular formula 
was established as C14H25N3O based on HRESIMS (obsd [M + H]+ at m/z 252.2075), 
implying 4 degrees of unsaturation. The UV absorption spectrum of 2 showed an 
absorption band at 300 nm, which was identical with the UV data obtained from 
nocarimidazols A (1). The IR spectrum of 2 was also identical to that of 1. The 1H 
NMR spectrum of 2 was almost identical to that of 1 except for the presence of one 
additional methylene resonance and the presence of one methyl triplet (δH 0.84) and 
methyl doublet (δH 0.78). The 13C NMR data of 2 were also similar to those of 1 
except for additional carbon signals at C-14 [δC 36.5] (Table 2.2). The interpretation 
of 2D NMR spectroscopic data permitted the identification of the structure of 2. 
 
 
Figure 2.4 Chemical structure of nocarimidazole B (2) 
 
To confirm the imidazole moiety of compound 2, methyl derivative (3) was 
prepared with diazomethane. A down field singlet (δH 3.42) was observed at 
1H NMR spectrum of compound 3 and the HMBC correlations from the 
singlet proton 3-NCH3 (δH 3.42) to C-2 (δC 130.9) and C-4 (δC 144.6) was 
clear to assign the position of N-3 within imidazole ring. However, to clarify 
the position of rest of nitrogen, dimethyl derivative of compound 2 was 
22 
prepared with iodomethane. This dimethyl derivative (4) of compound 2 
showed two down field singlets and the HMBC correlations from the singlet 
proton 1-NCH3 (δH 3.95) to C-2 (δC 130.6) and C-5 (δC 107.8) established the 
position of N-1 in imidazole ring. Those HMBC correlations observed from 
methyl derivatives of nocarimidazole B clarify the position of nitrogens and 
quaternary carbons within the imidazole ring as shown in Figure 2.5. 
 
 
Scheme 2.1 Methylation reaction of nocarimidazole B (2) 
 
 
Figure 2.5 Key HMBC correlations of nocarimidazole B (2) 
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Table 2.2 Physical and spectral properties of nocarimidazole B (2) 
Red amorphous solid 
Molecular formula: C14H26N3O, 
HRFABMS: m/z 252.2075 [M+H]+ (calcd for 252.2076) 
IR (KBr) vmax: 3433, 3054, 2926, 2855, 1678, 1548, 1455, 1384, 1203, 1140, 839, 722 cm-1 
[α]D + 1.42° (C 0.42, MeOH) 




C, mult.b H (J in Hz) 
2 130.5, CH  7.75, s 









2.68, t (J = 7.4) 
8 24.1, CH2 1.62, q (J =7.4)  
9 26.9, CH2 1.26,m 
10 29.4, CH2 1.07, m 
11 29.5, CH2 1.26, m 
12 29.3, CH2 1.26,m 
13 34.3, CH 1.25, m 
14 36.5, CH2 1.05, m 1.23, m 
15 11.3, CH3 0.84, t (J = 9.0) 
16 19.1, CH3 0.78, d (J = 9.0) 
a 500 MHz for 1H NMR and 125 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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  2.2.2 Bioactivities of Nocarimidazoles A and B 
The cytotoxicities were evaluated with MTT assay on A498 and ACHN renal cancer 
cell lines, but no significant cytotoxicities were observed. There were no 
antibacterial activities either, on MIC assay. Interestingly, AChE inhibitory activity 






    2.3.1 Instruments and Data Collection 
The optical rotation was measured using a Autopol III (Rudolph Research, USA) 
polarimeter with a 5 cm cell. IR spectra were obtained with a Varian Scimitar Series. 
CD spectra were collected in a ChirascanTM-plus (Applied Photophysics, UK) 
spectrometer with a 0.5 mm pathlength rectangular cuvette. NMR spectra were 
recorded on Varian Inova NMR spectrometer (500 and 125 MHz for 1H and 13C 
NMR, respectively), using the signals of the residual solvent protons and the solvent 
carbons as internal references (δH 7.24 and δC 77.0 ppm for CDCl3). EI-MS spectra 
were measured on a JEOL, JMS-AX505WA mass spectrometer. Low resolution LC-
MS data were measured using an Agilent Technologies 6120 quadrupole LC/MS 
system with a reversed phase column (Phenomenex luna C18(2) 100 Å , 50 mm × 
4.6 mm, 5 μm) at a flow rate of 1.0 mL/min. Column chromatography was performed 
using Silica gel 60 (0.040 ~ 0.063 mm, Merch), normal-phase methods. The fractions 
were separated by WATERSTM 616 quaternary HPLC pump, WATERSTM 996 
photodiode array detector using an Phenomenex luna C18(2) (250 mm × 10 mm, 5 
μm) reversed-phase HPLC column. 
 
    2.3.2 Microorganism Isolation and Fermentation 
Nocardiopsis sp. (CNQ115) was isolated from marine sediments collected off the 
coast of southern California. It was classified according to 16S rRNA analysis with 
99.3% identity. Strain CNQ115 was cultured in 8 2.5-L Ultra Yield Flasks each 
containing 1 L of the medium (10 g/L of soluble starch, 2 g/L of yeast, 4 g/L of 
peptone, 10 g/L of CaCO3, 20 g/L of KBr, 8 g/L of Fe2(SO4)3·4H2O dissolved in 750 
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mL natural seawater and 250 mL of distilled water) at 25 °C with shaking at 150 
rpm. After 7 days, the broth was extracted with EtOAc and evaporated under reduced 
pressure to yield an extract of CNQ115 (1.2 g). 
 
    2.3.3 Extraction and Compound Isolation 
The crude extract (1.2 g) was subjected on open column chromatography on silica 
gel (30 g), eluted with a step gradient of dichloromethane and methanol. The 
dichloromethane/methanol (10:1) fraction contained a mixture of metabolites, which 
was purified by reversed-phase HPLC (Phenomenex Luna C-18 (2), 250×100 mm, 
2.5 mL/min, 5 μm, 100 Å , UV = 254 nm) using an isocratic solvent system of 45% 
CH3CN in H2O to afford nocarimidazols A (1, 18.0 mg) and B (2, 25.0 mg). 
 
    2.3.4 Methylation Reactions 
Nocarimidazole B Diazomethane Derivative (3); Freshly prepared diazomethane 
reagent (0.5 mL) was added to a 1 mL MeOH solution of 2 (5.0 mg) at 4 °C with 
stirring. This solution was gradually warmed to room temperature. After 2 h, the 
solvent was removed under vacuum to yield 3.0 mg of nocarimidazol B 
diazomethane derivative (3). 1H NMR (CDCl3): δH 6.94 (H-2, s, 1H), 3.42 (3-NCH3, 
s, 3H), 2.84 (H-7, t, J =8.4 Hz, 2H), 1.68 (H-8, q, J =7.7, 2H), 1.26 (H-9, m, 2H), 
1.26 (H-11, m, 2H), 1.26 (H-12, m, 2H), 1.24 (H-13, m, 1H), 1.07 (H-10, m, 2H), 
1.05, 1.22 (H-14, m, 2H), 0.82 (H-15, t, J =8.4, 3H), 0.79 (H-16, d, J =7.0, 3H), 
EIMS m/z  266 [M]+ 
Nocarimidazole Iodomethane Derivative (4); A solution of 6.0 mg (0.024 mmol) of 
nocarimidazol B in 0.5 mL of DMF An appropriate amount of 0.167 mmol of 
Potassium carbonate (7 eq) was added and the whole was methylated with 0.5 mL 
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of CH3I. Then the mixture was heated to 60oC for 24 h to gave 4.0 mg of crude 
product (66% yield), which were purified by reversed-phase HPLC (Phenomenex 
Luna C-18 (2), 250×10 mm, 2.5 mL/min, 5 μm, 100 Å , UV = 254 nm) using an 
gradient solvent system of water and acetonitrile from 20% Acetonitrile to 100% 
Acetonitrile to afford a methyl nocarimidazol B (4, 1.5 mg) 1H NMR (CDCl3): δH 
8.76 (H-2, s, 1H), 3.95 (1-NCH3, s, 3H), 3.66 (4-NHCH3, s, 3H), 2.66 (H-7, t, J =7.2 
Hz, 2H), 1.64 (H-8, q, J =7.4, 2H), 1.29 (H-8, m, 2H), 1.26 (H-11, m, 2H), 1.26 (H-
12, m, 2H), 1.25 (H-13, m, 1H), 1.23 (H-9, m, 2H), 1.05, 1.23 (H-14, m, 2H), 1.07 
(H-10, m, 2H), 0.85-0.76 (H-15, H-16, m, 6H), EIMS m/z  280 [M]+ 
 
    2.3.5 Bioassay Procedures 
      2.3.5.1 Cytotoxicity Test 
 The cytotoxicity test was performed for two human cancer cell lines, A498 and 
ACHN renal cancer, according to a previously published method19 with 
modifications. The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin at 37°C in a 
humidified atmosphere incubator (5% CO2 in air). Wells with DMSO were used as 
negative controls, and temsirolimus, sunitinib and gemcitabine were used as positive 
controls 
 
      2.3.5.2 MIC Assay 
A following seven bacterial strains were used: four Gram-positive (Staphylococcus 
epidermidis ATCC 12228, Micrococcus lutes ATCC 9341, Bacillus subtilis ATCC 
6633, S. aureus ATCC 65381) and three Gram-negative (Escherichia coli ATCC 
11775, Salmonella typhimurium ATCC 14028, Klebsiella pneumonia ATCC 4352). 
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These bacteria were inoculated in Mueller-Hinton agar media for 24 h at 37°C. The 
bacterial colony was cultivated into a 15 mL round tube containing 6 mL of Mueller-
Hinton broth media at 37°C and 225 rpm for 24 h. Test compound (1) and a positive 
control (gentamicin) dissolved in DMSO were added 100 μL of each to 96-well 
microtiter plate having 50 μL of Mueller-Hinton broth in rest well. The samples were 
serially diluted and 50 μL of bacterial Mueller-Hinton broth media adjusted to 
concentration of 1/100 diluted McFarland 0.5% standard. The 96-well was incubated 
for 24 h at 37°C. After then, the minimum inhibitory concentration (MIC) values 
were determined as the concentration of compounds at transparent well which inhibit 
the growth of bacteria. 
 
      2.3.5.3 Acetylcholinesterase Inhibitory Assay 
The AChE inhibitory activity was measured using the modified method of Ellman et 
al. Briefly, a reaction mixture containing 140 μL of sodium phosphate buffer (pH 
8.0), 20 μL of the test sample solution, and 20 μL of AChE was incubated for 15 min 
at 25°C. Following the incubation, the reaction was initiated by adding 10 μL of 
dithiobisnitrobenzoate (DTNB) and 10 μL of ACh and incubated for 10 min at 25°C. 
The hydrolysis of ACh was monitored and quantified in a spectrophotometer at 412 
nm to measure the formation of DTNB with thiocholine released by the enzymatic 
hydrolysis of ACh. Donepezil hydrochloride (Santa Cruz Biotechnology) was used 
as a positive control. The 50% inhibitory concentration (IC50) of the donepezil 
hydrochloride was 0.02 ± 0.004 μM. All reactions were performed in triplicate on 
96-well plates and recorded using a VERSA max plate reader (Molecular Devices). 
The percentage of inhibition was calculated as (1 – S/E) × 100, where E and S are 
the enzyme activities with and without the sample. 
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Chapter 3. Marine Natural Products from Mudflat-
Derived Actinomycetes 
  3.1 Introduction 
Actinomycetes have been a promising source of bioactive natural compounds 
for several decades (Bérdy, 2005). Soil-derived actinomycetes have 
traditionally been the main source of bioactive natural products. In the 1980s, 
the first marine-derived actinomycete, Rhodococcus marinonascens, was 
described (Helmke & Weyland, 1984). Since then, marine sediments from 
beach sand to the deep sea bottom have been good environmental sources for 
isolating actinomycetes, which provide diverse bioactive secondary 
metabolites (Fenical & Jensen, 2006). Mudflats, also known as tidal flats, are 
intertidal zones with deposited mud, which create a unique ecological niche. 
This wetland is covered with salt water one to two times a day and is exposed 
to strong sunlight, which causes extreme environmental changes for the 
organisms living there. Despite these harsh environmental conditions, this 
zone is crowded with various microbial communities due to the rich nutrients 
available from the land and from the seawater. This unique ecological niche 
could also be an excellent environment for diverse bacterial species, including 
actinomycetes (Kim et al., 2004), a situation that often leads to unique 
chemical structures with diverse biological activities. Recently, our group 
reported that a Streptomyces sp. isolated from tidal flat sediments collected 
on Anmyeon Island, located on the west coast of Korea, produced 
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biologically active sesquiterpenoids with an indene moiety, anmindenols A 
and B (Lee et al., 2014). 
 
 
Figure 3.1 Sesquiterpenoids isolated from mudflat-drived actinomycetes 
 
 Actinomycete-derived natural products have not been examined extensively to 
combat neurodegenerative diseases, but specific efforts are ongoing. One of the 
diseases being studied is Alzheimer’s disease (AD), which deteriorates cognitive 
function. The most common molecular target for drugs that act on the symptoms of 
AD is acetylcholinesterase (AChE) (Parsons et al., 2013). ChE inhibitors block the 
AChE enzyme and prevent the neurotransmitter acetylcholine (ACh) from being 
broken down by AChE, thereby increasing the level of ACh at the synapse and the 
duration and action of ACh. Thus far, few compounds that exhibit AChE inhibitory 
activity, such as geranylphenazinediol (Ohlendorf et al., 2012), elaiomycins B and 
C (Kim et al., 201), N98-1272A (Zheng et al., 2007), and cyclophostin (Kurokawa 
et al., 1993), have been isolated from Streptomyces species. 
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  3.2 Results and Discussion 
 As part of our continued research into bioactive secondary metabolites from marine 
actinomycetes on the Korean peninsula, Streptomyces sp. 10A085 was isolated from 
a mudflat sediment sample. Chemical investigation of this strain yielded three new 
natural products, anithiactins A-D (1-4). Here, we present details of the isolation of 
anithiactins A-D and their biological activities in terms of AChE inhibition. 
 Anithiactins are members of the 2-phenylthiazole class of natural products. 
The representative natural products belonging to this class are aeruginoic acid 
(Yamada et al, 1970), aeruginol (Yang et al., 1993) and the pulicatins (Lin et 
al, 2010). In particular, the chemical structures of the anithiactins are closely 
related to those of aeruginoic acid and the pulicatins. Aeruginoic acid, a 
fluorescent natural product, was isolated from the culture medium of 
Pseudomonas aeruginosa and displayed antihypotensive activity (Imai et al., 
1973). The pulicatins, isolated from a cone snail (Conus pulicarius) associate 
Streptomyces sp., showed G protein-coupled receptor 5-HT2B inhibition 
activity in the micromolar range.8 These natural products possess an OH 
group at C-2, whereas anithiactins have an N-methyl group. This aniline 




Figure 3.3 Known 2-phenylthiazole class natural products 
 
    3.2.1 Structure Elucidation of Anithiactins 
      3.2.1.1. Anithiactin A (1) 
Anithiactin A (1) was obtained as a yellowish amorphous solid. The molecular 
formula of 1 was established as C12H12N2O2S based on high resolution MS data. The 
1H NMR spectrum displayed a 1, 2-disubstituted benzene ring moiety [H-3 (δH 6.77, 
d, J = 7.8 Hz), H-4 (δH 7.32, ddd, J =7.8, 7.8, 1.3 Hz), H-5 (δH 6.67, dd, J = 7.8, 7.8 
Hz), and H-6 (δH 7.63, dd, J = 7.8, 1.3 Hz)]. The 1H NMR spectrum also showed a 
downfield singlet proton H-4′ (δH 8.04, s), and N-methyl and O-methyl singlets [2-
NHMe (δH 3.01, s), 7′-OMe (δH 3.96, s)]. The HMBC correlations from the singlet 
proton H-4′ (δH 8.04, s) to carbons C-2′ (δC 170.1), C-5′ (δC 146.1) and C-7′ (δC 161.7) 
and the molecular formula of 1 allowed the construction of a thiazole ring moiety 
(Figure 3.4). The connection between the 1, 2-disubstituted benzene ring moiety and 
the thiazole ring moiety was achieved using HMBC correlations from the aromatic 
proton H-6 and the singlet proton H-4′ to C-2′. Lastly, the attachment of the N-methyl 
and the O-methyl groups at C-2 and C-7′, respectively, based on HMBC correlations 
from the N-methyl singlet to C-2 and the O-methyl singlet to C-7′ completed the 








Table 3.1 Physical and spectral properties of anithiactin A (1) 
Yellowish amorphous solid 
Molecular formula: C12H12N2O2S, 
HRFABMS: m/z 249.0698 [M+H]+ (calcd for 249.0698) 
IR (film) vmax: 3303, 3122, 1727, 1580, 1491, 1446, 1214, 1173, 1104, 906, 753, 738 cm-1 
UV (MeOH) λmax (log ε): 209 (5.07), 222 (4.78), 247 (4.31), 286 (4.05), 383 (4.10) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
1 
C, mult.b H (J in Hz) 
1 114.3, C  
2 147.5, C  
2-NHMe 29.8, CH3 3.01, S 
2-NH  8.43, br s 
3 111.1, CH 6.77, d (7.8) 
4 131.9, CH 7.32, ddd (7.8, 7.8, 1.3) 
5 115.0, CH 6.67, dd (7.8, 7.8) 
6 129.4, CH 7.63, dd (7.8, 1.3) 
2′ 170.1, C  
4′ 125.1, CH 8.04, s 
5′ 146.1, C  
7′ 161.7, C  
7′-OMe 52.3, CH3 3.96, s 
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.2. Anithiactin B (2) 
 The molecular formula of anithiactin B (2) was obtained as C11H11N3OS on the 
interpretation of the protonated molecule at m/z 234.0701 [M+H]+ in the HRFABMS 
data. The 1H NMR spectrum of anithiactin B (2) was very similar to that of 1 except 
for the absence of an O-methyl singlet and the presence of two singlet protons (δH 
5.73, δH 6.88). The analysis of the 2D NMR spectroscopic data and the molecular 
formula of 2 indicated that anithiactin B had an NH2 group at C-7′ instead of a methyl 
ester. The structure of 2 was also confirmed using X-ray crystallographic data 
(Figure 3.6). Slow evaporation of a concentrated solution of 2 in hexane and CHCl3 
mixture yielded yellow needles. 
 
 




Figure 3.6 X-ray crystal structure of anithiactin B (2) 
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Table 3.2 Physical and spectral properties of anithiactin B (2) 
Yellowish needle 
Molecular formula: C11H11N3OS, 
HRFABMS: m/z 234.0701 [M+H]+ (calcd for 234.0701) 
IR (film) vmax: 3415, 3321, 3193, 1650, 1609, 1581, 1485, 1367, 1215, 1175, 988, 804, 751 
cm-1 
UV (MeOH) λmax (log ε): 211 (4.67), 219 (4.41), 247 (3.91), 287 (3.67), 383 (3.70) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
2 
C, mult.b H (J in Hz) 
1 114.9, C  
2 147.3, C  
2-NHMe 30.2, CH3 3.00, d (5.0) 
2-NH  7.74, br s 
3 111.3, CH 6.77, d (7.8) 
4 132.2, CH 7.35, ddd (7.8, 7.8, 1.4) 
5 115.9, CH 6.71, dd (7.8, 7.8) 
6 130.0, CH 7.64, dd (7.8, 1.4) 
2′ 170.5, C  
4′ 122.9, CH 8.08 s 
5′ 149.2, C  
7′ 162.9, C  
7′-NH2  5.73, 6.88 br s 
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.3. Anithiactin C (3) 
 The 1H NMR spectrum of anithiactin C (3) was almost identical to that of anithiactin 
A (1) except for the absence of the O-methyl group. The molecular formula of 3 was 
established as C11H10N2O2S based on the HRFABMS data, indicating 3 had 14 Da 
less mass than anithiactin A. These data suggested that 3 had an OH group instead 
of an O-methyl group at C-7′. Interpretation of the 2D NMR spectroscopic data 
permitted the assignment of structure 3. 
 
 




Table 3.3 Physical and spectral properties of anithiactin C (3) 
Yellowish amorphous solid 
Molecular formula: C11H10N2O2S, 
HRFABMS: m/z 235.0543 [M+H]+ (calcd for 235.0541) 
IR (film) vmax: 3417, 2923, 1573, 1492, 1383, 1285, 1214, 1172, 750 cm-1 
UV (MeOH) λmax (log ε): 211 (4.56), 219 (4.30), 261 (3.63), 286 (3.57), 379 (3.57) nm 
1H and 13C NMR dataa (CD3OD) 
No. 
3 
C, mult.b H (J in Hz) 
1 116.5, C  
2 148.8, C  
2-
NHMe 
29.9, CH3 2.84, s 
2-NH  4.51, br s 
3 112.1, CH 6.64, d (7.8) 
4 132.6, CH 7.14, ddd (7.8, 7.8, 1.3) 
5 116.1, CH 6.49, dd (7.8, 7.8) 
6 130.5, CH 7.50, dd (7.8, 1.3) 
2′ 170.3, C  
4′ 123.1, CH 7.83, s 
5′ 154.9, C  
7′ 170.2, C  
a 600 MHz for 1H NMR and 125 MHz for13C NMR. b Numbers of attached protons were determined by 
analysis of 2D spectroscopic data. 
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      3.2.1.4. Anithiactin D (4) 
 The LRMS of anithiactin D was 423 and 445, which suggest 422 as molecular 
weight. The 1H NMR spectrum displayed a 1, 2-disubstituted benzene ring moiety 
[H-6″ (δH 7.32, d, J = 7.8 Hz), H-7″ (δH 7.04, dd, J = 7.8, 7.8 Hz), H-8″ (δH 6.94, dd, 
J = 7.8, 7.8 Hz), and H-9″ (δH 7.48, d, J = 7.8 Hz)]. The 1H NMR spectrum also 
showed a 1, 2, 4-trisubstituted benzene ring moiety [H-3 (δH 6.74, d, J = 7.8 Hz), H-
4 (δH 7.42, dd, J = 7.8, 1.3 Hz), and H-6 (δH 7.76, d, J = 1.3 Hz)]. The 1H NMR 
spectrum also showed downfield singlet protons H-4′ (δH 8.07), H-2″ (δH 7.27) and 
one N-methyl singlet [2-NHMe (δH 2.96, s)]. The upfield signals showed two 
methines [H-10″ (δH 4.27, d, J = 7.0 Hz) and H-11″ (δH 4.41, ddd, J = 7.0, 7.0, 4.2 
Hz)] and one methylene [H-12″a (δH 3.61, dd, J = 7.0, 4.2 Hz) and H-12″b (δH 3.48, 
dd, J = 7.0, 4.2 Hz)]. The HMBC correlations from singlet proton H-4′ (δH 8.07, s) 
to carbons C-2′ (δC 171.7), C-5′ (δC 150.6) and C-6′ (δC 165.6) allowed the 
construction of a thiazole ring moiety. The HMBC correlations from H-6 (δH 7.76, 
s) to carbons C-2 (δC 147.0), C-4 (δC 134.2), C-5 (δC 130.8) and C-2′ (δC 171.7) 
attached thiazole ring with 1, 2, 4-trisubstituted benzene ring. The HMBC 
correlations from singlet proton H-2″ (δH 7.27, s) to carbons C-3″ (δC 117.8), C-4″ 
(δC 128.2), C-5″ (δC 137.9) and C-6″ (δC 112.2) with 1, 2-disubstituted benzene ring 
allowed the construction of a indole moiety. The connection between the indole 
moiety and phenyl thiazole was achieved using HMBC correlations from the methine 
proton H-10″ to carbons C-4, C-5, C-4′, C3″ and C-4″. The COSY correlations from 
H-11″ (δH 4.41, ddd, J = 7.0, 7.0, 4.2 Hz) to H-10″ (δH 4.27, d, J = 7.0 Hz) and H-






Figure 3.8 COSY and key HMBC correlations of anithiactin D (4) 
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Table 3.4 Physical and spectral properties of anithiactin D (4) 
Yellowish amorphous solid 
Molecular formula: C22H22N4O3S (interpretation of NMR and LRMS data) 
LRMS: m/z 423 / 445 
1H and 13C NMR dataa (CD3OD) 
No. 
4 
C, mult.b H (J in Hz) 
1 115.4, C  
2 147.0, C  
2-NHMe 30.0, CH3 2.96, s 
3 112.0, CH 6.74, d (7.8) 
4 134.2, CH 7.42, dd (7.8, 1.3) 
5 130.8, C  
6 131.3, CH 7.76, d (1.3) 
2′ 171.7, C  
4′ 123.3, CH 8.07 
5′ 150.6, C  
6′ 165.6, C  
2″ 123.1, CH 7.27, s 
3″ 117.8, C  
4″ 128.2, C  
5″ 137.9, C  
6″ 112.2, CH 7.32, d (7.8) 
7″ 122.3, CH 7.04, dd (7.8, 7.8) 
8″ 119.5, CH 6.94, dd (7.8, 7.8) 
9″ 119.8, CH 7.48, d (7.8) 
10″ 45.6, CH 4.27, d (7.0) 
11″ 75.6, CH 4.41, ddd (7.0, 7.0, 4.2) 
12″ 66.2, CH2 3.61 d (7.0, 4.2) 
  3.48 d (7.0, 4.2) 
a 700 MHz for 1H NMR and 150 MHz for13C NMR. b Numbers of attached protons were determined by 




    3.2.2 Synthesis of Anithiactin A (1) 
 To further investigate the underlying biology of AChE inhibition using the 
anithiactins, a three -step synthetic route (Scheme 1) was developed for anithiactin 
A (1) using commercially available reagents. Thiobenzamide (6) was obtained from 
the sulfur substitution reaction of the anthranilamide (5) in 89% yield, which was 
then treated with bromopyruvate in dimethylformamide, a known thiazole ring 
formation reaction, to give thiazole 7 (Hoveyda et al., 2011). To achieve the selective 
N-monomethylation of 7, we first attempted to use common methylation reagents, 
such as methyl iodide, n-butyl lithium and sodium cyanoborohydride. These 
methylation reagents gave the N-dimethyl product of thiazole 7. Next, a solution of 
formaldehyde in dichloroethane and acetic acid was used as a mild methylation 
reagent for thiazole 7. The reaction mixture was stirred overnight, and sodium 
triacetoxy borohydride at 0°C was added. The mixture was left at room temperature 
for 2 h and yielded the N-monomethyl product (1) (Bonjouklian et al., 2004). The 
physical and spectroscopic data of the synthesized product were identical to the data 
for the natural product anithiactin A (1). 
  
45 
Scheme 3.1. Synthesis of anithiactin A (1) 
 
    3.2.3 Bioactivities of Anithiactins 
 A number of previous studies demonstrated that AChE inhibitory activity was 
improved by replacing a phenyl or oxazole with the thiazole moiety (Nagal et al., 
1995; Ronco et al., 2009). Recently, a thiazole containing AChE inhibitor, 
acotiamide (Acofide), was launched in Japan and is in preparation for phase III 
clinical trials in the EU (Nolan & Scott, 2013). Therefore, we examined the AChE 
inhibitory activities of anithiactins A-C (1-3) using the modified method of Ellman 
et al. (1961). Anithiactins A-C displayed AChE inhibitory effects with IC50 values 
of 63, 53, and 68 μM respectively. We also evaluated the cytotoxicity of the 
anithiactins against cancer cell lines. The three anithiactins did not show any 
significant cytotoxicity against A-498 and ACHN human cancer cell lines up to 200 




Figure 3.9 Acetylcholinesterase inhibitors containing thiazole moiety (Compound 




  3.3 Experimental 
    3.3.1 Instruments and Data Collection 
UV spectra were recorded in MeOH on a Scinco UVS-2100. The IR spectra were 
obtained using a Thermo Electron, Nicolet 5700 spectrometer. NMR spectra were 
obtained using Bruker Avance DPX-500 or DPX-600 spectrometers. CHCl3 (H 7.26; 
C 77.0) and MeOH (H 3.31; C 49.3) resonances were used as internal references. 
The HRFABMS were determined on a JEOL, JMS-600W spectrometer. The 
solvents used were EP grade products from Dae-Jeong & Metals Co., Korea. HPLC 
grade solvents were purchased from Burdick & Jackson Co. Medium-pressure liquid 
chromatography was performed on EM Science silica gel (230−400 mesh). TLC was 
performed using EM Science precoated silica gel plates (Merck 60 F254). The 
separation of extracts using an HPLC Waters 515 pump and a Waters 996 photodiode 
array detector was carried out using MG2 C18 (250 × 10 mm, 5 μm). The chemical 
reagents used for synthesis were purchased from Aldrich and TCI. All culture media 
were purchased from BD. 
 
    3.3.2 Microorganism Isolation and Fermentation 
 Streptomyces sp. 10A085 was obtained from marine sediments from Jaebu Island, 
GyeongGi-Do, South Korea in 2010. The sampled mud sediments were dried in air 
for 24 h on a clean bench and given a heat shock at 55 °C for 5 min to eliminate other 
bacteria. Aggregated clumps were lightly mortared using a glass rod and stamped 
onto various solid agar substrates. Some of the dried samples were suspended in 
sterilized seawater, and the diluted suspension was spread on variously prepared 
solid agar substrates using a disposable plastic rod. These crude plates were placed 
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in a 27 °C chamber and monitored for 1 to 3 months to obtain unique actinomycete-
like colonies. Strain 10A085 was picked from an ISP medium 4 agar plate containing 
white spores. The 16S gene was cloned using universal primers 27F and 1492R and 
showed 99% (1350/1357) similarity to Streptomyces sp. HV10 (accession no. 
KM881709). 
 
    3.3.3 Extraction and Compound Isolation 
 Strain 10A085 was cultured at 25 °C with shaking at 150 rpm in 24 Pyrex flasks, 
each containing 1 L of SYP medium (10 g soluble starch, 4 g yeast extract, and 2 g 
peptone dissolved in 1 L of 75% filtered natural seawater from Incheon, Korea). 
After 10 days, the broth was extracted twice using EtOAc, and the solvent was dried 
in vacuo to yield 2.6 g of extract. The extract (2.6 g) was separated using a silica 
column-equipped MPLC and step-gradient elution of MeOH in CH2Cl2 (0%, 1%, 
2%, 5%, 10%, 20%, 50%, 90% and 100%). Fraction 1 was further purified using 
reversed-phase HPLC (MG2 C18 
280 nm; CH3CN:H2O = 70:30) to obtain 1.0 mg of anithiactin A (1). Fraction 3 was 
also purified using the same column, eluting with 98% CH3CN in H2O to afford 
anithiactin B (2, 3.0 mg). Anithiactin C (3, 3.0 mg) was isolated from fraction 8 with 
the same isolation procedure used for anithiactin B. 
 
    3.3.4 X-ray Crystallographic Analyses 
 The single-crystal X-ray diffraction data of the compound was collected with a 
Bruker SMART APEX CCD detector employing graphite-monochromated Mo Kα 
radiation (λ = 0.71073 Å) at 273(2)K. The data collection and integration were 
performed using SMART (Madison, WI, 2000) and SAINT-Plus (Madison, WI, 
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2001). The structure was solved using direct methods and refined using full-matrix 
least-squares on F2 using SHELXTL (Madison, WI). All the non-hydrogen atoms 
were refined anisotropically, and hydrogen atoms were added to their geometrically 
ideal positions.  
Anithiactin B (2): yellow needle; C11H11N3OS, Mr = 233.30, monoclinic, a = 
15.1825(12) Å, b = 5.2022(4) Å, c = 14.7674(12) Å, α = 90°, β = 111.728(2)°, γ = 
90°, V = 1083.50(15) Å 3 , space group P2(1)/c, Z = 4, Dx = 1.430 mg/m3 , μ(Cu Kα) 
= 0.279 mm−1, and F(000) =488. Crystal dimensions: 0.18 × 0.14 × 0.12 mm3. 
Independent reflections: 2677 (Rint = 0.0825). The final R1 values were 0.0644, wR2 
= 0.1544 (I > 2σ(I)). CCDC number: 1022818. 
 
    3.3.5 Synthesis Procedures 
 Sulfur Substitution Reaction of Anthranilamide (5);  A solution of anthranilamide 
(5, 200 mg, 1.47 mmol) and the Lawesson reagent (320 mg, 0.8 mmol) in THF (10 
mL) was stirred under N2 at r.t. for 24 h. The reaction mixture was partitioned 
between EtOAc (15 mL) and 2 N HCl (15 mL). A saturated aqueous NaHCO3 
solution was added to the separated aqueous layer until pH 8 – 9 and extracted with 
EtOAc (2 × 20 mL). The combined organic layer was dried with MgSO4 and filtered. 
The solvent was evaporated in vacuo and the thiobenzamide (6) was obtained after 
silica gel column chromatography (n-Hexane:EtOAc = 3:1). 
Thiobenzamide (6): 200 mg (1.31 mmol, 89%), yellow amorphous solid; 1H NMR 
(700 MHz, CD3OD): δ ppm 6.67 (dd, J = 7.0, 7.0 Hz, 1 H), 6.78 (dd, J = 7.0, 1.2 Hz, 
1 H), 7.14 (ddd, J = 7.0, 7.0, 1.2 Hz, 1 H), 7.26 (dd, J = 7.0, 1.2 Hz, 1 H); 13C NMR 
(175 MHz, CD3OD): δ ppm 118.4, 118.9, 126.9, 128.2, 132.5, 147.8, 203.8; 
LRESIMS m/z 153 [M + H]+ 
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 Formation of Thiazole (7);  To a solution of thiobenzamide (6, 100 mg, 0.66 mmol) 
in DMF (10 mL) was added bromopyruvate (70 µL, 0.66 mmol). The mixture was 
stirred under N2 at 65 °C for 2 h. The reaction mixture was partitioned between 
EtOAc (20 mL) and saturated aqueous NH4Cl solution (20 mL). The aqueous layer 
was extracted with EtOAc (2 × 20 mL) and combined organic layer was dried with 
MgSO4 and filtered. The solvent was removed in vacuo and the thiazole (7) was 
obtained after silica gel column chromatography (nHexane:EtOAc = 3:1). 
Thiazole (7): 100 mg (0.42 mmol, 65%), pale yellow amorphous solid; 1H NMR (700 
MHz, CDCl3): δ ppm 3.94 (s, 3 H), 6.70 (dd, J = 7.0, 7.0 Hz, 1 H), 6.78 (d, J = 7.0 
Hz, 1 H), 7.19 (dd, J = 7.0, 7.0 Hz, 1 H), 7.59 (d, J = 7.0 Hz, 1 H), 8.05 (s, 1H); 13C 
NMR (175 MHz, CDCl3): δ ppm 55.3, 114.7, 116.8, 116.9, 125.2, 129.1, 131.4, 
145.9, 146.4, 161.7, 167.8; LRESIMS m/z 235 [M+H]+ 
 Monomethylation of Thiazole (7);  Add formaldehyde (10 mg, 0.33 mmol) to a 
mixture of thiazole (7, 40 mg, 0.17 mmol), acetic acid (1 mL) and 1, 2-
dichloroethane (10 mL). The reaction mixture was stirred overnight at r.t. and 
sodium triacetoxyborohydride (55 mg, 0.26 mmol) was added at 0°C. The reaction 
mixture was stirred for 2h at r.t. and partitioned between EtOAc (10 mL) and 
saturated aqueous NaHCO3 solution (20 mL). The aqueous layer was extracted with 
EtOAc (2 × 20 mL) and combined organic layer was dried with MgSO4 and filtered. 
The solvent was removed in vacuo and the anithiactin (1) was obtained after silica 
gel column chromatography (n-Hexane:EtOAc = 4:1). 
Anithiactin A (1): 18 mg (0.17 mmol, 43%), yellow amorphous solid; 1H NMR (700 
MHz, CDCl3): δ ppm 3.01 (d, J = 7.4 Hz, 3 H), 3.96 (s, 3 H), 6.66 (dd, J = 7.0, 7.0 
Hz, 1 H), 6.76 (d, J = 7.0 Hz, 1 H), 7.32 (dd, J = 7.0, 7.0 Hz, 1 H), 7.63 (d, J = 7.0 
Hz, 1 H), 8.04 (s, 1 H), 8.41 (br, 1 H); 13C NMR (175 MHz, CDCl3): δ ppm 29.8, 
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52.3, 111.0, 114.3, 115.0, 125.1, 129.44, 131.9, 146.1, 147.6, 161.7, 170.2; 
LRESIMS m/z 249 [M+H]+ 
 
    3.3.6 Bioassay Procedures 
      3.3.6.1 Cytotoxcity test 
 The cytotoxicity test was performed for two human cancer cell lines, A498 and 
ACHN renal cancer, according to a previously published method19 with 
modifications. The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin at 37°C in a 
humidified atmosphere incubator (5% CO2 in air). Wells with DMSO were used as 
negative controls, and temsirolimus, sunitinib and gemcitabine were used as positive 
controls 
 
      3.3.6.2 Acetylcholinesterase Inhibitory Assay  
 The AChE inhibitory activity was measured using the modified method of Ellman 
et al. Briefly, a reaction mixture containing 140 μL of sodium phosphate buffer (pH 
8.0), 20 μL of the test sample solution, and 20 μL of AChE was incubated for 15 min 
at 25°C. Following the incubation, the reaction was initiated by adding 10 μL of 
dithiobisnitrobenzoate (DTNB) and 10 μL of ACh and incubated for 10 min at 25°C. 
The hydrolysis of ACh was monitored and quantified in a spectrophotometer at 412 
nm to measure the formation of DTNB with thiocholine released by the enzymatic 
hydrolysis of ACh. Donepezil hydrochloride (Santa Cruz Biotechnology) was used 
as a positive control. The 50% inhibitory concentration (IC50) of the donepezil 
hydrochloride was 0.02 ± 0.004 μM. All reactions were performed in triplicate on 
96-well plates and recorded using a VERSA max plate reader (Molecular Devices). 
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The percentage of inhibition was calculated as (1 – S/E) × 100, where E and S are 
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A.1 Antibacterial Secosteroid from the Korean Sponge 
Irchinia sp. 
  A.1.1 Introduction 
 Marine Sponges are known as a source of structurally diverse natural products. This 
phylum of marine animal is possessing about 35% of reported marine natural 
products (Blunt et al., 2012). Many of the potent cytotoxins against cancer cell lines 
have been reported and some of them were developed as a lead of FDA approved 
drugs such as Cytosar-U® , and Halaven®  (Martins et al., 2014). The antibacterial 
activity of marine sponge-derived metabolites are also well known such as 
discorhabdin Z (Jeon et al., 2010), agelasine D (Hertiani et al., 2010), 7,20-
diisocyanoadociane (Wright et al., 2011), motualevic acid F (Keffer et al., 2009). In 
this regard, we have been investigated extracts of Korean marine sponges for the 
discovery of antibacterials. An extract of a Korean marine sponge in genus of Ircinia 
sp. showed antibacterial activities, and we continue the investigation of its bioactive 
constituents. 
 The genus Ircinia have been studied intensively and number of  biologically active 
natural products have been reported such as antibacterials (Manes & Crews, 1986; 
Faulkner, 1973), cytotoxin (Kondo et al., 1992), ichthyotoxin (De Rosa et al., 1996), 
analgesic compound (Cimino et al., 1972; De Pasquale et al., 1991), multidrug 
resistance modulator (Kawakami et al., 2001), thrombin inhibitor (Nakao et al, 1995), 
angiotensin converting enzyme/aldose reductase inhibitor (Alfano et al., 1979), and 
inosine monophosphate dehydrogenase inhibitor (Cafieri et al., 1972; De Rosa et al., 
1997). 
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 Also, this Ircinia sp. is well known for its possession of divers terpenes such as 
ircinin-1,7 variabilin (De Rosa et al., 1996), fasciculation (Cafieri et al, 1972), and 
strobilinin (Rothberg & Shubiak, 1975). In addition, hydroquinones (Cimino et al, 
1972a; Cimino et al. 1972b), chromans (Venkateswarlu & Reddy, 1994; Bifulco et 
al., 1995), and sterols (Venkateswarlu et al., 1996; Fu et al., 1999; Xu et al., 2008) 
have been reported. However, the organisms in Ircinia sp. was not reported for its 
secostrols. 
 Herein, we report the structure of an unprecedented secosterol with the 2-ene-1,4-
dione as well as its antibacterial activity. 
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  A.1.2 Results and Discussion 
    A.1.2.1 Structure Elucidation of 9,11-Secosterol (1) 
 The molecular formula of compound 1 was deduced as C27H44O5, based on the 
analysis of HRFABMS data (a pseudomolecular ion peak at m/z 449.3271 [M+H]+) 
and on the interpretation of 13C NMR data. The 1H NMR spectrum of 1 displayed an 
oxygenated methine proton [δ 4.04 (m)], an olefinic proton [δ 6.49 (br s)], and one 
downfielded methylene protons [δ 3.84 (m). 3.70 (m)]. The 1H NMR spectrum also 
showed two methyl singlets [δ 1.23, 0.70] and three methyl doublets [δ 0.97 (d, J = 
6.6 Hz), 0.88 (d, J = 2.3 Hz), 0.86 (d, J = 2.3 Hz)]. The 13C NMR and HSQC spectra 
revealed five methyl, ten methylene, six methine, and six fully-substituted carbons. 
The 27 carbons, five methyl protons, and an oxygenated methine proton are 
characteristic of a cholesterol carbon skeleton. Furthermore, 1H NMR signals of an 
olefinic proton δ 6.49 (s, 1H), oxymethylene protons [δ 3.70 (m, 1H), δ 3.84 (m, 
1H)], a downfield proton [δ 3.52 (dd, 1H, J = 11.0, 8.5 Hz)], and five methyls [δ 0.70 
(s, 3H), δ 1.23 (s, 3H), δ 0.97 (d, 3H, J = 6.6 Hz), δ 0.88 (d, 3H, J = 6.6 Hz), δ 0.86 
(d, 3H, J = 6.6 Hz)] suggested that 1 was a 9, 11-secosterol. 
 Interpretation of 2D NMR spectroscopic data permitted the structure assignment of 
1. Analysis of COSY spectroscopic data of 1 revealed three fragments (a, b, and c) 
as shown in Figure A.1.1. In addition, the carbon chemical shifts of C-6 (δ 197.5), 
C-7 (δ 134.4), C-8 (δ 152.1), and C-9 (δ 203.1), and the HMBC correlations from an 
olefinic proton H-7 to carbons C-6, C-8, and C-9 supported the construction of an 
ene-dione moiety. 
 The connectivity of A/B ring including the fragment a and the ene-dione moiety for 
1 was secured from HMBC correlations. The long-range HMBC correlations from 
63 
H-19 to carbons C-1, C-5, C-9, and C-10, and from H-4 to carbons C-2, C-5, and C-
10, and from H-7 to the carbon C-5 allowed the A/B ring connectivity. The fragments 
b and c were also connected from the interpretation of HMBC correlations. A two-
bond HMBC correlation from a methyl singlet proton H-18 to a carbon C-13, and 
three-bond HMBC correlations from H-18 to carbons C-12, C-17 permitted the C-
12/C-13/C-17 connectivity. Lastly, the establishment of C-8/C-14 attachment based 
on the interpretation of three-bond HMBC correlations from the olefinic proton H-7 
to a carbon C-14, and from the methyl singlet proton H-18 to a carbon C-14 allowed 
the completion of structure assignment of 1. (Figure A.1.2) 
 
 
Figure A.1.1 COSY and key HMBC correlations of 9,11-secosterol (1) 
 
 
Figure A.1.2 Chemical structure of 9,11-secosterol (1) 
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 The relative stereochemistry of the side chain and rings of 1 was identical to that of 
reported secosterols, which was determined by comparison with NMR data of known 
secosterols and by interpretation of NOESY correlations (Reddy et al., 1997; Lu & 
Faulkner, 1997). Briefly, NOESY correlations [H-7/H-14, H-14/H-12, H-12/H-21, 
H-18/H-20] were well corresponded to previously reported NOE correlations (Anta 
et al, 2002). The β-configuration of 3-hydroxy group at C-3 was defined from the 
coupling constants of H-4 (δ 2.16, dd, J = 13.1, 11.2 Hz) and NOESY correlations 
[H3/H4, H4 2.16)/H19]. (Figure A.1.3) 
 
 
Figure A.1.3 Key NOESY correlations observed for 9,11-secosterol (1) 
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Table A.1.1 Physical and spectral properties of 9,11-secosterol (1) 
Colorless needles 
Molecular formula: C27H44O5, 
HRFABMS: m/z 449.3271 [M+H]+ (calcd for 449.3275) 
IR (film) vmax: 3422, 2951, 2851, 1718, 1681, 1464, 1633 cm-1 
UV (MeOH) λmax (log ε): 274 (3.96) nm 
1H, 13C, COSY and HMBC NMR dataa (CDCl3) 
No. C, mb H, m, J (Hz) COSY HMBC (JCH = 10 Hz) 
1 25.9, t 1.77 m  
2.21 dt (11.2, 3.7) 
2 3, 5, 10, 19 
2 29.8, t 1.55 m  
2.00 m 
1, 3  
3 66.6, d 4.04 m 2, 4  
4 35.6, t 1.77 m  
2.16 dd (13.1, 11.2)  
3 2, 5, 10 
5 80.5, s    
6 197.5, s    
7 134.4, d 6.49, s   5, 6, 8, 9, 14  
8 152.1, s    
9 203.1, s    
10 52.1, s    
11 59.9, t 3.70 m;  
3.84 m  
12  
12 41.1, t 1.11 m 
1.73 m 
11  
13 47.5, s    
14 43.9, d 3.52 dd (11.0, 8.5) 15 7, 8, 9, 12, 13, 15, 18 
15 26.3, t 1.75 m  
1.84 m 
14, 16  
16 26.6, t 1.68 m  
1.75 m 
15, 17  
17 50.1, d 1.73 m 16, 20  
18 17.7, q 0.70 s  12, 13, 14, 17  
19 20.6, q 1.23 s  1, 5, 9, 10 
20 34.5, d 1.41 m 17, 21, 22  
21 18.8, q 0.97 d (6.6) 20 17, 20, 22 
22 35.6, t 0.99 m  
1.35 m 
20, 23 24 
23 24.4, t 1.15 m 
1.35 m 
22, 24  
24 39.4, t 1.13 m 
1.15 m 
23, 25  
25 27.9, d 1.51 m 24, 26, 27 23 
26 22.5, q 0.86 d (6.6) 25 24, 25, 27,  
27 22.7, q 0.88 d (6.6) 25 24, 25, 26 
5-OH  2.36 br s   
 a 600 MHz for 1H NMR and 150 MHz for 13C NMR 
b Multiplicity was determined by the analysis of 2D NMR spectroscopic data 
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    A.1.2.2 Antibacterial Activity of Secosterol  
 Compound 1 was evaluated for antibacterial activity against seven pathogenic 
strains. (Table A.1.2) Compound 1 displayed the most potent activity on 
Micrococcus lutes ATCC 9341 and also showed the moderate activity against 
Staphylococcus epidermidis ATCC 12228 and Bacillus subtilis ATCC 6633 with 
MIC values of 3.1, 25 and 25 μg/mL, respectively. Meanwhile, 1 did not show any 
activity against gram negative strains include Escherichia coli ATCC 11775, 
Salmonella typhimurium ATCC 14028 and Klebsiella pneumonia ATCC 4352 up to 
200 μg/mL. Interestingly, growth of one of the gram positive strain Staphylococcus 
aureus ATCC 65381 was not inhibited up to 200 μg/mL. 
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Table A.1.2 Antibacterial activity of 9,11-secosterol (1) 
Strain 1a Gentamicin a 
Staphylococcus epidermidis ATCC 12228 25 0.2 
Micrococcus lutes ATCC 9341      3.1 3.1 
Bacillus subtilis ATCC 6633 25 0.2 
S. aureus ATCC 65381 >200 0.2 
Escherichia coli ATCC 11775 >200 0.8 
Salmonella typhimurium ATCC 14028 >200 1.6 
Klebsiella pneumonia ATCC 4352 >200 0.8 




  A.1.3 Experimental 
    A.1.3.1 Instruments and Data Collection 
 The optical rotation was measured using a Rudolph Research Autopol III 
polarimeter with a 5 cm cell. The UV spectrum was recorded in a Scinco UVS-2100 
with a path length of 1 cm. Infrared spectra were recorded on a Thermo Electron 
Corporation spectrometer. NMR spectral spectroscopic data were obtained using 
Bruker Avance 600 MHz spectrometer [CDCl3 (δH 7.26; δC 77.0) was used as an 
internal standard]. HRFABMS data were measured on a JEOL, JMS-AX505WA 
mass spectrometer. 
 
    A.1.3.2 Animal Material 
The genus Ircinia sponge was collected by scuba diving at Yeongdeok-Gun in the 
East Sea. The sample was frozen immediately after collection with dry ice and stored 
in refrigerator at -20 °C before extraction.  
 
    A.1.3.3 Extraction and Isolation 
 The wet animal (3 kg) was extracted three times with 50% methanol (MeOH) in 
dichloromethane. These extracts were concentrated and partitioned three times 
between hexanes and MeOH. Then the MeOH-soluble layer was partitioned three 
times between ethylacetate (EtOAc) and water. The water-soluble fraction was 
further extracted thrice with n-butanol. The EtOAc-soluble layer (7.0 g) was 
subjected to silica flash column chromatography using step-gradient elution of 
EtOAc in hexanes (0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 
100%) to afford seven fractions (Fr 1-Fr 11). Fr 5 (68.3 mg), which contained the 
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mixture of 1, was further purified by reversed-phase HPLC (Polar-RP, 250 × 10 mm, 
5 μm, 80 Å, 2.5 mL/min, UV detection = 210 nm), eluting with 70% acetonitrile in 
H2O to afford compound 1 (2.7 mg), as colorless needles. 
 
    A.1.3.4 MIC Bioassay Procedures 
 The six microorganisms were obtained from the stock culture collection at the 
American Type Culture Collection (Maryland): The antibacterial activity was 
determined by the 2-fold microtiter broth dilution method (Wiegand & Hilpert, 
2008). Dilutions of the test compounds dissolved in DMSO were added to each well 
of a 96-well microtiter plate containing a fixed volume of Mueller Hilton broth (final 
0.64% DMSO). Each well was inoculated with an overnight culture of bacteria (5 × 
105 cfu/mL), and the plate was incubated at 37 °C for 24 h. The minimum inhibitory 
concentration (MIC) was taken as the concentration at which no growth was 
observed.
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A.2 NMR spectra of 9,11-Secosterol A 
 
Figure A.2.1 1H NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.2 13C NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 150 MHz) 
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Figure A.2.3  COSY NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.4  HSQC Spectrum of 9,11-Secosterol A 
 (CDCl3, 600 MHz) 
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Figure A.2.5  HMBC NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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Figure A.2.6  NOESY NMR Spectrum of 9,11-Secosterol A 
(CDCl3, 600 MHz) 
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B.1 NMR Spectra of Nocrimidazoles A and B 80 














B.1 NMR Spectra of Nocrimidazoles A and B 
 
Figure B.1.1 1H NMR Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.2 13C NMR Spectrum of Nocarimidazol A (1) 
(CDCl3, 125 MHz) 
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Figure B.1.3   COSY Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.4 HSQC Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.5 HMBC Spectrum of Nocarimidazol A (1) 
(CDCl3, 500 MHz) 
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Figure B.1.6 1H NMR Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.7 13C NMR Spectrum of Nocarimidazol B (2) 
(CDCl3, 125 MHz) 
 
88 
Figure B.1.8 COSY Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.9 HSQC Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.10 HMBC Spectrum of Nocarimidazol B (2) 
(CDCl3, 500 MHz) 
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Figure B.1.11 1H NMR Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.12 COSY Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.13 HSQC Spectrum of Nocarimidazole B 




Figure B.1.14 HMBC Spectrum of Nocarimidazole B 
Diazomethane derivative (3) (CDCl3, 700 MHz) 
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Figure B.1.15 1H NMR Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
 
96 
Figure B.1.16 COSY Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
 
97 
Figure B.1.17 HSQC Spectrum of Nocarimidazole B 
Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.18 HMBC Spectrum of Nocarimidazole B 












Figure B.1.3 COSY Spectrum of Nocarimidazol A (1) (CDCl3, 500 MHz)  
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Figure B.1.16 COSY Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.17 HSQC Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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Figure B.1.18 HMBC Spectrum of Nocarimidazole B Iodomethane Derivative (4) (CDCl3, 700 MHz) 
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B.2 NMR Spectra of Anithiactins A-D 
 
Figure B.2.1 1H NMR  spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.2 13C NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.3 COSY spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.4 HSQC NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.5 HMBC NMR spectrum of Anithiactin A  
(CDCl3, 600 MHz) 
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Figure B.2.6 1H NMR spectrum of Anithiactin B  
(CDCl3, 600 MHz) 
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Figure B.2.7 13C NMR spectrum of Anithiactin B  
(CDCl3, 600 MHz) 
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Figure B.2.8 1H NMR spectrum of Anithiactin C  
(CDCl3, 600 MHz) 
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Figure B.2.9 13C NMR spectrum of Anithiactin C  
(CDCl3, 600 MHz) 
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Figure B.2.10 1H NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.11 COSY NMR Spectrum of Anithiactin D 
(CD3OD, 700 MHz) 
 
112 
Figure B.2.12 HSQC NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.13 HMBC NMR Spectrum of Anithiactin D  
(CD3OD, 700 MHz) 
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Figure B.2.14 1H NMR spectrum of synthetic intermediate 6 
(CDCl3, 600 MHz) 
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Figure B.2.15 13C NMR spectrum of synthetic intermediate 6 




Figure B.2.16 1H NMR spectrum of synthetic intermediate 7 
(CDCl3, 600 MHz) 
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Figure B.2.17 13C NMR spectrum of synthetic intermediate 7 
(CDCl3, 600 MHz) 
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Figure B.2.18 1H NMR spectrum of synthetic Anithiactin A 
(CDCl3, 600 MHz) 
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Figure B.2.19 13C NMR spectrum of synthetic Anithiactin A  






























Figure B.2.7 13C NMR spectrum of Anithiactin B (CDCl3, 600 MHz) 
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Figure B.2.10 1H NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.11 COSY NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.12 HSQC NMR Spectrum of Anithiactin D (CD3OD, 700 MHz) 
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Figure B.2.14 1H NMR spectrum of synthetic intermediate 6 (CDCl3, 600 MHz) 
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Figure B.2.15 13C NMR spectrum of synthetic intermediate 6 (CDCl3, 600 MHz) 
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Figure B.2.16 1H NMR spectrum of synthetic intermediate 7 (CDCl3, 600 MHz) 
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Figure B.2.17 13C NMR spectrum of synthetic intermediate 7 (CDCl3, 600 MHz) 
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Figure B.2.18 1H NMR spectrum of synthetic Anithiactin A (CDCl3, 600 MHz) 
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 해양천연물은 원천생물의 다양성에 기반한 신약후보물질의 새로운 
공급원으로 각광받고 있다. 스쿠버다이빙이나 유인잠수정과 같은 기술의 
발전에 힘입어 관심이 더해지고 있으며, 현재 8 종의 해양신약이 개발되었다. 
대부분의 해양신약은 해양무척추동물로부터 분리된 해양천연물에 기반하여 
개발되었으나, 최근에 들어 실제적인 생산자가 해양미생물인 것이 알려지게 
되었다. 이 연구에서는 다양한 해양환경에서 분리된 방선균에서 신규한 
생리활성 해양천연물을 분리하였다. 
 미국 캘리포니아 연안의 퇴적물에서 분리한 Nocardiopsis sp. 
CNQ115 에서 2 개의 새로운 이미다졸 천연물인 nocarimidazole A 와 B 를 
분리하였다. Nocarimidazole A 와 B 의 화학구조를 NMR 을 이용하여 
결정하였다. 항균활성과 항암활성을 확인하였으나, 주목할만하지 않다. 
서해의 갯벌에서 Streptomyces sp. 10A085 를 분리하여 화학 조성물을 
분석하였다. 새로운 티아졸 천연물 anithiactin A – D 를 분리하여 NMR 을 
이용하여 화학구조를 결정하였다. Anithiactin B 는 X-ray 결정구조분석을 
같이 수행하였다. Anithiactin A – C 는 acetylcholinesterase 를 저해하는 
활성을 보였으며, 세포독성은 관찰되지 않았다. 
  
